Sea Snail Venom: A Potential Alternative to Opioid Analgesics

By

Faiyaz Ahasan

ID: 17146006

A project submitted to the Department of Pharmacy in partial fulfillment of the requirements

for the degree of Bachelor of Pharmacy (Hons.)

Department of Pharmacy,

Brac University,

April 2021

Declaration

It is hereby declared that

1. The project submitted is my original work while completing Bachelor of Pharmacy at Brac University.

2. The project does not contain material previously published or written by a third party, except where this is appropriately cited through full and accurate referencing.

3. The project does not contain material that has been accepted or submitted for any other degree or diploma at a university or other institution.

4. I have acknowledged all primary sources of help.

Student's Full Name & Signature:

Faiyaz Ahasan

17146006

Student Full Name
Student ID

Approval

The project titled “Sea Snail venom: A Potential Alternative to Opioid

Analgesics.” submitted by-

Faiyaz Ahasan, ID: 17146006

of Spring, 2017 has been accepted as satisfactory in partial fulfillment of the requirement for the degree of Bachelor of Pharmacy on May 2nd, 2021.

Examining Committee:

Thesis Supervisor:

Md. Tanvir Kabir
Senior Lecturer
Department of Pharmacy, Brac University

Program Coordinator:

Professor Dr. Hasina Yasmin
Professor, Department of Pharmacy
Brac University

Departmental Chairperson:

Professor Dr. Eva Rahman Kabir
Chairperson, Department of Pharmacy
Brac University

Ethics Statement

Hereby, I, Faiyaz Ahasan, actively assure that for the project that this review work entitled "Sea Snail venom: A Potential Alternative to Opioid Analgesics." is submitted for the fulfillment of the requirements for the degree of Bachelor of Pharmacy (Hons.) from the Department of Pharmacy, Brac University, signifies my work under the supervision of Md. Tanvir Kabir, Senior Lecturer, Department of Pharmacy, Brac University, and I have been given adequate credit where I have included others' words, insights, or writings. No animals were used or harmed in this project.

Abstract

The marine environment is a large and complex source for novel medicines. Conopeptides are present in sea snail venoms that have been detected to block pain by activating a separate molecular mechanism exploited by opioid painkillers. Researchers created a chemical version of the peptide by studying the conopeptide of cone snail called *Conus magus*. The synthetic form of the hydrophilic conopeptide 5-007-MVIIA used in the Pacific fish-hunting snail toxin, *Conus magus*, is ziconotide (also known as SNX-111). Intrathecal ziconotide is indeed a new, useful, and long-lasting dosage form that can be used for symptomatic relief of extreme persistent cancerous as well as non-malignant pain. It has been approved as an analgesic by the FDA (Food and Drug Administration and is currently used in the United States. The complications usually induced by opioids in pain treatment are likely to be overcome by using this analgesic agent.

Keywords: Marine; Opioid; Painkiller; Ziconotide; Conopeptide; Snail

Dedication

Dedicated to my Parents, Md. Humayun Kabir and Farhana Kabir.

Acknowledgment

First and foremost, I would like to praise and thank Allah (SWT), the Almighty, who has granted countless blessings, knowledge, and opportunity to me so that I have been finally able to accomplish the thesis. Apart from my efforts, the success of this thesis depends largely on the encouragement and guidelines of many others. I take this opportunity to express my gratitude to the people who have been instrumental in completing this thesis.

I am grateful to my respected supervisor, Md. Tanvir Kabir, Senior Lecturer, Department of Pharmacy, Brac University, for supporting me continuously and giving me the motivation to complete the project paper. Without his support, it was not possible to finish my project work. I am also grateful to Prof. Dr. Eva Rahman Kabir, Honorable Chairperson, Department of Pharmacy, and Brac University, for giving me the support and opportunity to complete my project work and B.Pharm program.

Table of Contents

List of Tables

List of Figures

List of Acronyms

ADR	Adverse Drug Reaction
NSAID	Nonsteroidal anti-inflammatory drug
RA	Rheumatoid Arthritis
OA	Osteo Arthritis
OTC	Over the Counter
TrKA Receptor	Tropomyosin receptor kinase A
COX II	Cyclooxygenase-2
cAMP	Cyclic Adenosine Monophosphate
cGMP	Cyclic Guanosine Monophosphate
CSF	Cerebrospinal Fluid
BBB	Blood-Brain Barrier
IT	Intrathecal
NMDA	N-methyl-D-aspartate
VASP	Vienna Ab initio Simulation Package

Chapter 01

Background

Our body reacts to noxious stimuli in the form of pain. It is the combination of both physical and mental responses generated by the body. When there is a risk of potential injury, our body warns us through this response by means of influence to avoid such stimuli. It is difficult to enumerate pain as it is idiosyncratic in a sense (Woolf, 1995). A significant feature of pain is always to notify the individual of substantial risks. This is achieved by nociception, the neurological treatment of noxious stimuli. That being said, the pain sensation is indeed one aspect of the nociceptive response, which may involve increased blood pressure, a rapid heart rate, and an instinctive detachment from the external stimuli (Kynast et al., 2013).

Acute pain can occur through cracking the bone or even from contacting a hot surface. Under acute pain, an unpleasant, uncomfortable sensation of a small period, also mentioned mostly as a sharp lacerating feeling, is followed by a gradual pulsating feeling. Chronic pain, mostly correlated with illnesses such as cancer or inflammation, is much more difficult to figure and control. Psychosocial processes, including chronic depression, may enhance the severity of pain that cannot be relieved. Despite the situational aspect, much of the pain is consistent in muscle injury and seems to have a clinical foundation. For instance, while the skin is susceptible to burns and slashing, the visceral regions may be sliced without creating damage (Fornasari, 2012). Chemical stimulation of the different touchpoints might, nevertheless, trigger pain. Certain organs may not feel pain, regardless of how they would be triggered. The liver and lung bronchioles are resistant to nearly any stimuli. Thereby, tissues adapt to anything other than the particular stimuli that they really are prone to undergo and are typically not responsive to all forms of injury. Pain is indeed a mental and emotional part of human nature, so humans have also been identified since the earliest eras, but the forms wherein the

individuals react to it, and the concept of pain differ drastically (Davis & Mehta, 2016). In some of these indigenous cultures, for instance, suffering was purposely performed on individuals as a means of placating angered gods. The pain was also used as a type of torment performed upon humanity by gods or spirits. In Chinese civilization, suffering was believed to result from the conflict between the two fundamental powers of living: yin and yang. Avicenna, a Muslim practitioner, claimed how pain was a symptom that coincided with a shift in the external system of the body. The different disease causes severe pain throughout the treatment procedures. Rheumatoid arthritis, osteoarthritis, fibromyalgia are considered for being liable; however, chronic pain could even be triggered by tumors, muscular dystrophy, stomach problems, AIDS (Acquired immunodeficiency syndrome), and gastrointestinal disorders (Chen & Sehdev, 2019). The pain generated due to cancer can be observed at a certain point, mostly during the progression of the illness, while this prevalence and severity of cancer pain continues to worsen as cancer advances. Among older patients, 62%–86% suffered extreme pain, which is defined as mild too extreme in roughly 40%–50% and quite extreme throughout 25%–30%. Bone cancer pain has been the most frequent pain in older patients (Li et al., 2018).

A good number of patients with metastatic cancer disorder report extreme pain; while the bone is also not a critical organ, most prevalent tumors have a clear proclivity for bone metastases. Bone tumor development results in pain, hypercalcemia, anemia, increased vulnerability to illness, structural instability, contractures, spinal weakness, and diminished movement — many of which undermine patient longevity and wellbeing (Coleman 2006, 2008). When cancer cells eventually start to spread to the bone, pain is typically characterized as subdued in nature, persistent in appearance, yet steadily growing in severity over the period. When tumor-induced bone renovating advances, extreme event pain also arises, and as the emergence of that kind of pain is both immediate and erratic, this aspect of bone cancer pain can be excruciatingly painful to the patient's functioning health and quality of life. Occurrence or breakout pain,

described as such a rare event of unbearable pain, can occur randomly or is far more typically caused by any activity or mass-bearing, mostly on tissue-bearing bones (Andrade & Mantyh, 2010). Pain management is done in different ways through medications and therapies. Primarily, opioid analgesics are used for the pain management of cancer patients, which leads to severe side effects and adverse effects, and eventually, death is the destination sufferers find after struggling for years (Hoffmann et al., 1995).

Chapter 02

Global Impact of Severe Pain Due to Cancer

Cancer pain is some of the most prominent, dreaded, disabling, and sometimes inadequately treated signs in people with cancer. It deserves care because it has a direct effect on the Quality of Life of individuals. Furthermore, while cancer has now arisen mostly as a health threat throughout developed countries, hence the need to improve prevention measures for successful treatment of cancer pain and to offer relief to people with cancer (Raffaeli & Arnaudo, 2017). However, multiple hurdles restrict developed countries to the optimum treatment of cancer pain. To close the difference between effective pain control and the stress of cancer pain in developed nations, a thorough awareness of the limits and incidence of cancer pain need proper care (Li et al., 2018).

Cancer is a major reason for death worldwide, accounting for an estimated nine million people deaths in the last three years (Chwistek, 2017). The most prominent type of cancers includes lung (around 2 million incidents), breast (around 2 million incidents), colon cancer event (around 1 million incidents), prostate (around 1 million incidents), skin cancer (around 1 million incidents), stomach (around 1 million cases). Most common factors that cause death from cancer includes lungs (around 1.7 m deaths), colorectal (around 850 000 deaths), stomach (around 780 000 deaths), liver (around 780 000 death), breasts (around 630 000 deaths) (Plummer et al., 2016).

Table 1- Prevalence of cancer pain in different parts of the world

Region	Study Design	N – Sample size	Age (years)	Gender	Type of cancer	Key findings	References
Taiwan, ROC (Asia)	Cross-sectional	2,075	Mean (SD) 57.47 (13.2)	Mean (SD) Males: 992 (47.81) Females: 1,083 (52.19)	Head and neck cancers. - Gastrointestinal and colon/rectum cancers. -Hepatobiliary and pancreas cancers. -Breast cancer Lung and mediastinum cancers. - Blood/lymphoma. -Genitourinary cancer Others.	>75 percent of patients with pain recorded satisfied with their doctor and pain treatment, but several individuals also experienced pain.	(Rau et al., 2015)
Jordan (Middle East)	Cross-sectional	162	Mean (SD) 47.6 (15.1)	Males: 51% Females: 49%	-Leukemias and lymphomas. -Solid tumors	The incidence of pain within people with cancer in Jordan was marginally higher than in other areas of the world. Pain has been under care.	(Li et al., 2018)
China (Asia)	Cross-sectional	643	Mean (SD) 58.74 (14.01)	Males: 56% Females: 44%	-Lung cancer -Breast cancer -Colon and rectum cancers -Gastric cancer -Liver cancer Pancreatic cancer.	More than 50% of patients had moderate/severe pain. Most of the patients were satisfied with pain treatment	(Li et al., 2018)

					-Bladder cancer Uterus and ovarian cancers -Esophageal cancer -Bone tumor Lymphoma Others		
Korea (Asia)	Survey	7,507	Range <65–74	Males: 55% Females: 45%	-Pancreatic cancer -Carcinoma of unknown origin -Liver cancer -Lung cancer -Multiple myeloma -Head and neck cancers -Esophageal cancer -Breast cancer -Colorectal cancer -Stomach cancer -Cervical cancer -Lymphoma -Leukemia	Cancer pain correlates with performance status and cancer stage but not significantly with age	(Kim, 2019)
Lebanon (Middle East)	Cross-sectional	100	Mean (range) 51.5 (18–85)	Males: 49% Females: 51%	-Hematological cancers -Lung cancer -Gastrointestinal cancer -Breast cancer	The pain was one of the most commonly reported symptoms	(Halawi et al., 2012)

Yemen (Middle East)	Retrospective	50	Mean age Female 49.8 years Male 56.9 years	Males: 68% Females: 12%	-Colorectal carcinoma	The prevalence of colorectal cancer in Yemen was higher than the annual incidence in Jordan and Lebanon	(Harhra & Basaleem, 2012)

Chapter 03

Impact of Severe Pain Due to Cancer in Bangladesh

Bangladesh has not reached the standard position from where we can say our cancer management is satisfactory. Then comes the pain associated with it. Patients here suffer greatly due to it, as the overpopulation does not enable us to treat each patient equally with intensive care and manage their pain and sufferings without much delay (Walco et al., 1994). Bangladesh, with 142 million inhabitants, has been the ninth most inhabited country on the planet. There have been 13 -15 lac cancer sufferers in Bangladesh, with approximately two lac cancer patients reportedly reported every year. In addition, lung cancer, as well as oral oropharynx cancer, are among the main two common cancers in males. Some examples of cancers include esophageal cancer as well as stomach cancer. Women had one of the most common diseases of the cervix uteri, also breast cancer. Many forms of cancer that impact females include oral cancer including cancers of the mucosal lip, tongue, gum, and lung associated cancer (Hussain, 2013).

Chapter 04

Pathophysiology of Pain

Intense inflammation seems to be the natural physiological reaction expected for an unfortunate molecular, kinetic, or physical stimulation. It stems from the induction of sensory nerves (nociceptors) also at the tissue injury site. One such form of pain typically includes surgery, severe injuries, organ destruction, and inflammatory pathways. Intense inflammation plays a crucial function in delivering alert signs that anything is wrong and needs further study. It really is a peer and settles throughout weeks or months, although it will linger indefinitely when healing progresses. Intense inflammation can stimulate that feeling of pleasure or disappointment, including its central nervous system that causes responses including agitation, hypothyroidism, dysuria, rapid breathing, sleeplessness, external grimace, protecting, paleness, as well as dilated pupils (Raffaeli & Arnaudo, 2017). Pain in reaction to tissue injury is a common condition and therefore, can be correlated with severe, inappropriate physical, spiritual, and social pain. Insufficiently regulated pain is sometimes a consideration throughout the progression of chronic pain. Unpleasant impulses may be sensed through nociception, which are independent nerve cells of cells in the body. Both provide providing examples and in standard circumstances, just adapt to acute inflammation. There seem to be two different kinds of nociceptors (Lynch et al., 2006).

Strong thresholds mechanoreceptors to activate tiny myelinated Afferent nerve and relay a well-located, painful, or pinching feeling what takes as long as its stimulation. Polymodal nociceptors that trigger thin, non - myelinated, slow-moving C fibers. Including reacting to mechanical stimulus, thermochemical stimulation being triggered. The transcription factors for electrical stimulation have indeed been partly recognized, the TRP family of such signaling pathways but in particular that TRPV1(Transient Receptor Potential Cation Channel Subfamily

V Member 1) is already examined in detail (Foreman et al., 2015). The whole receptor is responsive to extreme temps, acidity, and chlorine; external binding sites and regulators of this kind are actively being researched. Neural expression levels also become active throughout the sensor when it attaches to the Tropomyosin receptor kinase A transmitter and hence causes enhanced transduction throughout suffering environments, in addition to inflammatory pain (Schug et al., 2011). Sodium-plated impedance pathways arbitrate deformation between key sensory afferents. Like with all other stimuli in the system, the possible spread of activity relies upon those networks. There will be two groups of ion channels that vary in response to tetrodotoxin (Campbell & Meyer, 2006). Almost all forms remain active in excitatory neurotransmitters, also with tetrodotoxin-resistant form mostly existing in mechanoreceptors, rendering it a possible focus with novel painkillers. Some more study has established two certain sodium channels, called, what does have a particular function throughout the regulation of pain (Gross et al., 2019).

Seven defects of both these pathways are related to idiopathic intolerance to pain, and measures are taken to find inhibitors of those same sites, which could be helpful in persistent or neurological disorders. Nociceptors often have a voltage-closed calcium pathway that is located mostly on cell neurons and is implicated mostly in the development of neurotransmission to the nucleus accumbent (Bolay & Moskowitz, 2002). Both are modified through alpha-2-delta molecules, including certain gabapentin as well as pregabalin, recent first therapies for neuropathy and core sensitization. Pain is expressed through main afferents whose cells are in the dorsal root ganglion. Which wind up mostly in spinal cord. This same dorsal horn cells are classified into different cultures or laminae designated as Rexed's laminae, another very simplistic of which is lamina I (Schug et al., 2011).



Figure 1- Pathology of Pain (Dinakar & Stillman, 2016)

Chapter 05

Drugs Commonly Used for Pain Management

There seems to be a range of choices regarding the management of intense pain. There are medicinal remedies for persistent pain throughout the broad group of drugs. Orally taken medications are among which can be ingested by mouth, like NSAIDs (non-steroidal anti-inflammatory drugs), acetaminophen, or opioids. Drugs that may be added to the body surface, such as a lotion or gel or even a patch that is applied topically, are still appropriate (Wiffen et al., 2017). Many of these patches function by just being put specifically over the sore region in which the active substance, like lidocaine, gets delivered. Other groups, including such opioid patches, can be found further from the region of pain. Few medicines might be available as over-the-counter drugs, and others may need a prescription. There are many forms of medicines available to relieve severe pain. In addition, some concerns regarding the dose and health issues of such medicines can be addressed by the regular practitioner, clinical care expert as well as pharmacist (Vieira et al., 2019). The most widely prescribed drugs could be categorized into large groups:

5.1 NSAID Drugs with Acetaminophen: There are several common forms of Nonsteroidal anti-inflammatory (NSAID) drugs that can also be given Over the counter. NSAIDs can become very useful in severe bone and muscle pain and even certain forms of severe pain. If used for an extended amount of time or even insignificant doses, drugs can have harmful impacts mostly on the liver, blood clotting as well as Gastrointestinal tract (Klein et al., 2012). Bleeding ulcers are a possibility with any of these medicines (Gupta & Bah, 2016). Lengthy-term usage of cyclooxygenase -II inhibitors can also be correlated with such an improvement in cardiac (heart) threat. Acetaminophen remains readily available OTC. Nevertheless, caution must be exercised to never consume upwards of 4000 mg within a day. Otherwise, multiple

liver problems can cause (Campbell & Meyer, 2006). There are also several prescription medicines that incorporate acetaminophen with either the medicine. Patients ought to be mindful that some OTC drugs have acetaminophen as being one of their components when it is used in conjunction mostly with the prescription drug. It can really contribute to such an excess of acetaminophen (Klein et al., 2012).

5.2 Antidepressants: Several of the earlier types of antidepressants could be very effective in the prevention of pain, especially tricyclic antidepressants. The pain healing effects of all these products really are that they too can alleviate pain at levels smaller than with the dosage required to manage anxiety. Such medicines really aren't supposed for use "if required" but should be used often, whether or not the patient has any pain (Kremer et al., 2016). Doctors can try to minimize a few of the adverse effects, especially palpitations, by taking medicine at nighttime. There are several other health risks, such as sore throat, which can be handled through drinkable water or liquids. Such treatments will not be provided to people with some forms of glaucoma. In fact, such medicines can never really be administered at greater concentrations than recommended (Kremer et al., 2018).

5.3 Anticonvulsants medicines: Certain treatments are very effective for those forms of neural-type pain (including such swelling, stabbing pain). Such drugs are often not intended to be taken on even a "when required" level. These can be administered daily if they experience pain or otherwise. Any of it can also have a secondary effect of somnolence, which also shows the extent. Any of these have the secondary effect of obesity. If he/she has kidney stones or colitis, should immediately notify the specialist that if any anticonvulsants really aren't prescribed in certain circumstances. Relatively new anticonvulsants shouldn't need hepatitis control but still need care when offered to patients having a renal impairment (Gross et al., 2019).

Muscle Relaxants: Such products are most widely employed in severe muscle spasm conditions. The most frequent consequence of these products is somnolence.

5.4 Opioids: Opioids is very helpful in treating some forms of debilitating pain when it's used properly. These appear to be somewhat successful or need an increasing dosage of neural-type pain. For the event of pain, sustained-release opioid is typically prescribed throughout the day and overnight. Among the worst side effects is constipation, which, although moderate, can be controlled with a ton of fluid yet do need to be managed with drugs (Wiffen et al., 2017). Sleep deprivation is yet another adverse effect that also constantly changes when the patient getting accustomed to the drug. Unnecessarily high sleepiness must be shared with the specialist. Nausea is yet another adverse effect that can be challenging to manage, and that may entail a shift to some other medication (Bovill, 1997).

Chapter 06

Mechanism of Action of Opioids

Opioids and NSAIDs are the most prominent medicines being used to relieve pain. Opioids imitate the behavior of natural opioid peptides through binding via opioid markers. Opioid receptors form linked with Gi proteins, and drug activity is primarily effective in inhibiting. That shut N-type calcium-operated voltage pathways as well as expand Ca-dependent inwardly-correcting potassium channels. That leads to hyperpolarization as well as decreased neuronal excitability. These often lower their intracellular cAMP (Cyclic adenosine monophosphate) that attenuates the activation of neuronal receptors; for example, substance P. Blockade of prostaglandin synthesis through cyclo-oxygenase seems to be the adaptive system of reliving pain system of opioids. Cyclo-oxygenase remains irrevocably blocked by aspirin but is covalently blocked by many NSAIDs (Campbell & Meyer, 2006). The pervasive suppression of cyclooxygenase being liable for much of the health consequences of such medications. Opioids often lower the amount of prostaglandin inside the Nerves (Urquhart, 1993). This really is the key aspect of opioids (Freye et al., 2008). Opioids are also known as GPC receptors, which ideally bind to G protein-sensitive pertussis over one and sometimes more of 3 signaling pathways, cytoplasmic unrestricted Calcium ions+, Pi, and cAMP. Like many other G protein-coupled regulators, opioids provide seven-transmembrane covering regions as well as three additional 3 epithelial chains. Packed sequences in trans-membrane domains become essential to the binding site in G protein linking (Freye et al., 2008).

Opioids mainly work by inhibiting. They block N-type voltage-oriented calcium pathways and expand Ca^{2+} dependent inwardly-correcting potassium channels. That leads to hyperpolarization as well as decreased synaptic activity. Opioids frequently block adenyl cyclase, which transforms ATP (Adenosine triphosphate) to cAMP, which decreases the

intensity of cAMP. Adjustments in the cAMP could be important in the regulation of the activation of neurotransmission (McCormack, 1994). CAMP frequently stimulates and controls protein kinase C, which enhances its development of initial transitional mutations like c-fos. C-fos would be a predictor of development in neurons correlated with nociceptors and inhibited by morphine (Freye et al., 2008).



Figure 2- Mechanism of Action of Opioids (Freye et al., 2008)

Chapter 07

Major Problems Associated with Opioid Analgesics in Pain Management

Opioids are already known amongst the most powerful drugs for the reduction of pain throughout decades. Its usage throughout the treatment of acute extreme pain and persistent pain due to the advancement of medical conditions is assumed the quality of treatment in many other areas of the world. On another side, the lengthy-term usage of opioids to relieve persistent non-cancer suffering appears to be problematic (Wiffen et al., 2017). Problems associated with efficacy, protection, and misuse of duty have developed over the years, frequently contributing to a much more conservative outlook and often contributing to a stronger desire to accept such care (Vieira et al., 2019). Over the last few decades, views significantly changed in relation to psychiatric and statistical findings and incidents throughout the legal and legislative systems (Chwistek, 2017).

The relationship seen between valid medicinal usage of narcotics to produce an analgesic effect as well as the phenomenon connected with dependence and addiction tends to question the scientific establishment, contributing to confusion whatsoever about the effective function of such medications throughout the assessment of severe pain (Raffaeli & Arnaudo, 2017). This correlational study specifically explains the neurophysiology of narcotics and afterward reflects on the nuanced difficulties involved in that same relationship involving pain relief and addiction, like language, therapeutic concerns, as well as the ability to emerge medications, like buprenorphine, that can affect the procedure (Hoffmann et al., 1995). It is hard to evaluate the incidence of addiction conditions amongst chronic pain sufferers. According to a 1992 review article, indeed, seven reports using appropriate diagnosis parameters stated which rates of opioid usage problems amongst people with chronic pain varied from 3.2% to 18.9%. A

Swedish survey of 414 people with severe pain revealed about 32.8% were treated with opioid use disorder (Trescot et al., 2008). According to these two U.S. reports, 43 to 45 percent of people with chronic pain registered disordered drug-related actions, that percentage of curable opioid usage disorders remains uncertain (Chen & Sehdev, 2019). Every one of these findings examined people that have been admitted to pain centers, which could exaggerate the incidence of opioid misuse in the general community with severe pain. A comparatively high incidence of drug misuse problems in individuals with severe pain may also be derived from the high co-occurrence of these two disorders (Stein & Lang, 2009). Many other researchers have indicated that perhaps the incidence of severe pain in individuals with narcotics as well as other drug use problems is considerably greater than the incidence of pain in the overall population (Klein et al., 2012).

7.1 Opioid Addiction due to Overuse

Typically, opioids remain effective if one administers them properly. Although patients that do not obey their doctor's orders, also people abusing opioids might become addicts. The term addiction is known to be a disorder that influences the mind and gradually actions. Firstly, patients have the power of the intention to begin taking medications (Eitan et al., 2017). When one uses a medication, its stimulating impact can undoubtedly make him want to continue taking it. In reality, throughout the time, the brain is adjusting in some of these aspects such that the patient grows a strong desire to use that substance again and again (Jones et al., 2015). Narcotics are indeed a type of potent medication that is commonly used to relieve serious pain. When narcotics are exploited, these drugs can produce sensations of extreme joy or exhilaration but can often contribute to a drug overdose (Bovill, 1997).

Narcotics may be safe medications if taken as intended because they are in danger of being addicted due to their strong impact. Almost all street-derived and prescribed narcotics may be

misappropriated. Heroin has become a popular street drug that might be guzzled or burned, but it holds a more significant risk once ingested. Such threats involve the transmission of diseases like HIV (Human immunodeficiency virus) as well as hepatitis B and C. Through exchanging injections, skin diseases, damaged vessels, infectious diseases, and overdoses. Users may also use prescribed drugs by swallowing the drug and either swallowing, huffing or inserting it (Lee et al., 2016). Drug dependency requires upwards of mere chemical dependency. For instance, an individual having cancer who has been administered narcotics for extreme pain can suffer long-term side effects whenever the drug is discontinued and is therefore not addictive. Drug dependency often includes psychiatric abuse. It implies that perhaps the medication is so essential to an individual's existence also that desire to keep utilizing does become an addiction or urge, even though the patient recognizes that perhaps the usage is dangerous (Ling et al., 2011). Withdrawal symptoms, as well as increased resistance, may cause an individual to purchase illegal drugs than go to over yet another doctor to provide the same medication. Those who can smoke, snore, compress or inject drugs in individuals to enjoy stronger quicker and far more powerfully. This can impact their connection between relatives or associates or can lead an individual to overlook certain obligations (Wang, 2019).

Drug dependency is triggered by a mixture of physical and psychological causes. They shall include entry to narcotics through legitimate or illegitimate outlets, resistance to drugs (Dreifuss et al., 2013). The requirement of using a rising quantity includes compulsory usage, Signs of withdrawal, Signs, and symptoms for the production of drug dependency has, including Anecdotal evidence of drug use incidents related to some drug, even alcohols, family medical history of drug use disorders, or alcohol problems, history of pre-teen sexual assault, past of mental conditions (Jones et al., 2015).

7.2 Opioid Tolerance and Dependence due to Overuse

The institutional concept of tolerance would be a reduction in impact after persistent or extended administering of a given dosage. It is necessary to differentiate brief or 'severe' tolerances, which grow between moments to many days, from lengthy tolerances that evolve throughout increased sensitivity to narcotics (Eitan et al., 2017). The previous is potentially rather directly linked to pathways for accelerated hypersensitivity and exploitation of opioid derivatives than some others. Quantitatively, resistance is typically shown by a right-hand change in the receptor dosages graph following prolonged application over weeks or months (Chang et al., 2007). Its declines in effect may be attributed to pharmacologic or environmental processes. Researches reporting to prove that a new opioid generates fewer resistance than standard opioid painkillers may show that pharmacologic factors were not important. For instance, tolerance is definitely linked to the length of the sensitivity of μ-opioid receptors towards excessive drug concentrations, to a constant application, resulting in enhanced tolerance versus sporadic access (Morgan & Christie, 2011).

Limited research calculates medication levels just at updated accordingly (CNS) or monitors again for a period of operation of every other level. The accumulation of CNS (Central nervous system) is much less of an interest in animal experiments wherein active opioid application to particular areas of both the CNS, like the nervous system, induces tolerance. While repetitive opioid implementation causes certain variations in neuronal sensitivity from constant implementation, a relevant connection of sensitivity production with various inhibitors involves stable therapy with inhibitors achieving similar results throughout the CNS to maintain comparable degrees and length of receptor activation (Fishbain et al., 1992). Tolerance is often a relatively excellently adaptive reaction to narcotics and yet is entirely linked to pain relief. Organizationally, this is known as a lack of analgesic potency through increased production of addictive painkillers (Siegel, 1976). While simple to explain, it is just

a multidimensional construct. Exploring initial drug resistance incidents, scientists observed improvements in opioid-associated ion channels, including secondary transporter pathways in many neural regions (Whistler et al., 1999). Pharmacological mechanisms and genetic engineering methods have been utilized in vivo; however, evidence shows how many protein kinases are involved (Kieffer & Evans, 2002). Quite a few breakout animals display alterations of morphine sensitivity, which shows which genetic variants can affect this sensitivity only at the molecular level. More to exacerbate the scenario, during the 1970s, scientists showed that animals that produced morphine reactive with one setting just were not tolerant when evaluated in another, emphasizing the background as a significant element throughout the determination of sensitivity (Nestler, 1996).

The molecular and cellular foundation for this extensive approach to persistent opioids is difficult. Given the drawbacks, the estimation of tolerance is highly affected by opioid potency, with high-efficiency inhibitors having less evident sensitivity than low-efficiency agonists (Christie, 1991). The whole association is very well known across both acting species and independent cells. It occurs partially since extremely effective opioids achieve optimum impact with lower ensure reasonably (Christie et al., 2000). The effectiveness of receptor signaling for either therapy or challenge opioids frequently affects the degree of resistance as much as the efficiency of various endogenous signaling cascades. Low-level implementation relative to high-efficiency agonists generates stronger resistance to threat agonists independent of the effectiveness of agonists (Yaksh et al., 2016).

Drug dependency is detrimental to people as well as to culture overall. Dopamine is already suggested for being active, mostly in the process of drug dependency. In the meantime, while, some other hormone, serotonin, can also carry a function. In compliance mostly with dopamine tolerance theory, the results suggested a 30 to 50 percent decline throughout the supply of dopamine transporters for people with opioid dependency. Research often indicated

the same degree of rehabilitation following therapy. Serotonin has also been seen to have a powerful impact; again, data is quite sparse (Jones et al., 2015).

7.3 Respiratory Diseases Associated with Morphine Intake

Opioids being commonly often used as potential analgesic activities. About the treatment of severe and persistent pain, many disorders (Ling et al., 2011). The application of opioids is linked to adverse breathing symptoms that are sometimes related to distress in the brain and nervous system. The latest statistics suggest that drug consumption has risen over time over the past two decades (Kiyatkin, 2019). There is also rising proof opioids get a number of impacts, mostly on the lungs, apart from the repression of breathing. Narcotics can have an impact on inflammatory cell activation, stimulate the occurrence of histamine. This induces bronchospasm, vascular constriction, including oversensitivity responses; such acts include, combined, a variety of impacts on pulmonary function (Yamanaka & Sadikot, 2013). Regulation of pain plays a vital role in the management of pain—patients of progressive tumors and perhaps other incurable diseases, including acute post-surgical even persistent non-malignant conditions. Painkillers have been the most popular ones. Frequently recommended pain control in hospitals managing authorized usage of drugs shall therefore require patients suffering from opioid abuse (Kiyatkin, 2019).

This is primarily the application of opiates. Engender of drug usage is documented in 1 to 2 percent of sufferers, and painkiller misuse is a contributing factor to death. Morphine is a prototype of painkiller analgesic and over 20 years. Morphine was known to become the first medication of preference for the management of mild to extreme pain. Including experimental medication formulas, for instance, oxycodone, hydrocodone as well as fentanyl, the supply of different goods as well as the production of several opioids have changed all around the country. Either or not real or manufactured, opioid medications some basic functional

attributes, including morphine, pharmacological activity including attachment precision, Comparable sites for opioids. The Consequences of Both endogenous, as well as environmental opioids, tend to be found to rely mostly on form and the inclinations to the same form the receivers (Kiyatkin, 2019). The latest statistics suggest that drug usage has risen for the past 20 years. It is indeed growing clear, through the broader use, that their use is it is correlated with such a number of similar consequences. Generally speaking, A lot of such adverse effects, mostly on the cardiovascular system they were due to certain core neurological behavior. Nevertheless, the method is consistently documented; opioids can, however, influence the immune system Cells and raise inflammation, bronchial problems and vascular constriction, and oversensitivity responses. Such acts all of which have a multitude of Impacts on pulmonary function (Yamanaka & Sadikot, 2013).

7.4 Brain Hypoxia Associated with Opioid Intake

Brain hypoxia occurs anytime when the brain doesn't have sufficient oxygen. These might trigger while a person is underwater, coughing, asphyxiating, or even in a heart attack. Brain-related issues, stroke, even carbon monoxide toxicity are some other key indicators for brain hypoxia. This disorder may be significant since neurons require a consistent oxygen supply to operate efficiently. Narcotics are effective treatments for alleviating the suffering of many causes, although they have some significant detrimental propensity, including excessive usage at greater levels also leads to severe health problems. Respiratory failure, which contributes towards brain hypoxia, is probably the most controversial sign of immediate opioid toxicity that can contribute to deadliness (Kiyatkin, 2019). Respiratory Problems contributing to brain hypoxia tend to be among the most harmful consequences of opioids. Although the side-effect from opioids becomes minimal after their medicinal application, it is indeed a significant reason for significant morbidity and mortality once particularly potent opioid painkillers, including morphine or fentanyl being taken at massive doses through routes that include rapid

drug distribution to the CNS. It's also widely accepted that respiratory distress stems from either direct contact with opioid medications (Nadal et al., 2000).

Opioid receptors are primarily found in the respiratory tract, the central nervous system, and neurons. This critical mechanism demonstrates unequivocally that respiratory function quickly declines after intracerebral and scattered intracerebral microinjections of several opioids. It demonstrates a significant function for centrally positioned Opioid Receptors in the descending pathways that control breathing function. Even so, opioid receptors are indeed extensively distributed in sensory neurons afferents innervating capillaries, skin, and vital organs, like airways. Hence in accordance with the design goals, systemic delivery opioid medications interfere specifically with opioid receptors and alter the afferent signals to the CNS, thereby causing synaptic responses and contributing to resulting shifts in physicochemical measures. Because opioid medications interfere with both somatic and autonomic opioid receptors, opioid symptoms are contrasted (Kiyatkin, 2019).

Inhibitors may pass the blood-brain barrier (BBB) with others being unable to pass such border might have been an important method for investigating the function of nerve impulses in activating the neuronal and biochemical impact of opioids. Naloxone-HCl, an extremely active opioid blocker that readily passes the BBB and associates both to core and secondary opioid receptors (OR), totally prevents breathing difficulties and several other clinical and behavioral symptoms of opioids. Nevertheless, morphine-and fentanyl-induced respiratory impairment is often modulated through high-dose naloxone-methiodide, another quaternary version of opioids, which itself is known to be resistant to BBB and can therefore just interfere with both the secondary reservoir containing ORs. Naloxone-MET also another well-capable influencer of the nociceptors and induced gastric reactions caused through morphine, fentanyl, and oxycodone (Perekopskiy et al., 2020).

Chapter 8

Pain Medications During Pregnancy and Associated Risk Factors

Owing to concerns over the usage of medication through breastfeeding, certain pregnant people would choose to have pain instead of suffering. As a consequence, certain females could be in danger of undertreatment or just no medication for debilitating situations. Recurrent, extreme suffering that would be ineptly handled is linked with stress, sleep problems from which leads to something like stable childbirth (Babb et al., 2010). Opioids, for instance, morphine, hydrocodone, clonazepam, fentanyl, and oxycodone, meperidine-agonists, and psychoactive drug analogs, for example, tramadol (Shah et al., 2015). Hormonal research illustrating the usage of pain medications in human reproduction is reduced because there are no significant longitudinal similarities. However, these medications are being used in standard quantities among pregnant ladies several times but have not been correlated with an enhanced likelihood of significant or small abnormalities. The Joint Neonatal Initiative recorded 448 opioid doses throughout different phases of childbirth and observed minimal signs of elevated excitotoxic effects.

The research documented 336 infants subjected to hydrocodone, 286 addicted to oxycodone, and 7640 revealed to codeine, just in the initial weeks of pregnancy. This same prevalence of severe chromosomal abnormalities reached 4.6 percent again for the oxycodone-exposed category,4.9 percent also for morphine group (reliable only with wider population threat), and 7.2 percent for hydrocodone category, that might have been affected by mitigating variables like maternal illness incidence and associated substance use) There was no product research of 141 children with genetic heart abnormalities (Shah et al., 2015).

Chapter 9

Potential Risks for Cancer Patients Using Narcotics in Pain Management

Narcotic treatment is the first-line solution to mild or serious debilitating cancer pain. Although narcotics remain powerful analgesics, these remain psychologically harmful medicines. The community health consequences of opioid misuse encourage all doctors to take liability regarding risk control while certain medications being administered with appropriate medicinal reasons. When cancer advances to the final stages, non-opioid treatments may not be adequate to include the required analgesia, or the highest prescribed regular dosage might well be approached (Morrison & Morrison, 2006).

A number of defined acetaminophen variations are authorized in pharmaceutical markets, typically involving codeine, hydrocodone, oxycodone, including propoxyphene. Centered on comprehensive proof of effectiveness, such varieties also prescribed for the treatment of mild to extreme distress throughout that next phase of the WHO (World Health Organization) analgesic hierarchy (Reed, 2013). An appealing alternative of long-term pain therapy being the mixture between acetaminophen and tramadol, which has also been found to be quite successful in patients for a quicker initiation and prolonged time of operation than each portion alone, despite raising any occurrence of harmful incidents (Nersesyan & Slavin, 2007). However, this step involves a regular and continuous diagnosis to titrate increasing medication at a suitable dosage, which is usually restricted to the non-opioid portion. If the cap for such medications has been met, the first stage would be to shift into mere opioid medications (Alvarez et al., 2001).

Opioids being commonly the far more popular type of medication being used to relieve cancer pain. The function through connecting to μ-opioid sites inside the CNS responsible for causing

analgesia, respiratory impairment, sedation, physiological dependency, and immunity (Williams et al., 2001). The analgesic activity of narcotics is primarily based on μ-receptor exhaustion, which is therefore determined by the form and intensity of pain, previous sensitivity to opioids, including the human concentration of hormones (Ballantyne & Mao, 2003). There is really no optimum dosage for such operatives, and they are constrained mainly also by the occurrence of adverse effects that are unique to either the client's onset or intensity. Popular medication withdrawal symptoms cause nausea, indigestion, anesthesia, and pain, and may also be controlled through losing pain management by modifying the regular dose of both the medication or even in chronic situations, by implementing supplementary medicines including such stomach cramps metoclopramide, indigestion laxatives, as well as anesthesia clonazepam (Finch et al., 2000).

Continuous intake of narcotics can contribute to the creation of resistance and opioid-induced unusual oversensitivity (Dews & Mekhail, 2004). Scientific findings indicate that these manifestations may be linked with N-methyl-D-aspartate receptor-induced modifications throughout the CNS. Painkiller hypersensitivity or hypersensitization of N-methyl-D-aspartate receptors through extended opioid treatment can all lead to such an obvious decline in anti-inflammatory potency, independent of injury severity. Under certain circumstances, however, treatment of growing suffering with growing quantities of the same medication could be ineffective (Ballantyne and Mao 2003). While it hasn't been proven to be definitive in clinical environments, NMDA receptor blockers (ketamine, dextromethorphan, memantine, amantadine), including reduced opioid antagonists (naloxone, naltrexone) can partly counteract drug addiction (Nersesyan & Slavin, 2007). In addition, since cross-tolerance to narcotics is insufficient, drug substitution should often be utilized to resolve unintended harmful consequences of drug desensitization. Exogenous narcotics can often influence the physiological or immune systems with extended usage, contributing to diminished

fertility and additionally drive together with mild immunosuppression. Although in instances with severe cancer pain, certain harmful consequences of opioid treatment, alongside apprehension of opiate dependence and overdose, ought not to be deemed quite significant and do not preclude the practitioner from supplying the individual with sufficient pain relief (Morrison & Morrison, 2006).

Chapter 10

Non-Opioid Analgesics

Non-opioid painkillers are OTC and pharmaceutical medicines being used to treat pain. In some number of healthcare environments, these have been widely emphasized both as favored, reliable, and efficient, alternatives to prescription narcotics, including mild to severe moderate to severe pain. Paracetamol, aspirin as well as corticosteroid, anti-inflammatory medications (NSAIDs) seem to be the most popular non-opioid drugs (Finnerup, 2019). Brief application of short-dose drugs can be appropriate for the management of mild to serious, intense pain following an operation or catastrophic injury. Nevertheless, complications related to opioid usage, including the possibility for dependency and addiction, have driven physicians to seek non-opioid NSAIDs and also non-pharmacological options like psychodynamic treatment, activity treatment, even herbal medicine to relieve mild symptoms of acute and chronic suffering. CDC (The Centers for Disease Control and Prevention) recommendations endorse such approach, stating that non-opioid drugs are typically less correlated for drug dependence, abuse growth, and proposing "non-opioid as well as non-pharmacological medicines as recommended non-active chemotherapy drugs for persistent pain and preventative or finished care (Hsu et al., 2019).

Scientific studies are now promoting this approach. One analysis of patients with mild to extreme persistent nerve pain, joint or leg osteoporosis showed that perhaps the usage of opioid and non-opioid treatment does not contribute to substantially improved anguish control over a year. In comparison, patients consuming opioids mostly during analysis showed slightly further drug-related effects throughout 12 months than any of those consuming non-opioid medications (Berde & Sethna, 2002). Scientists further recommend how non-opioid Medications could become the norm of treatment among surgical patients to reduce the usage

of perioperative narcotics as well as to eliminate postoperative adverse reactions including nausea, vomiting, anesthesia, emesis, urticaria, and breathing distress. Such discovery is compatible with the improved rehabilitation following the surgical approach that advocates for multidisciplinary pain relief. Today's physicians provide a range of pharmaceutical and non-pharmaceutical choices for the management of pain. Among certain people with extreme serious pain, a basic course of medication tends to heal and stabilize. Among most patients with persistent extreme pain, narcotics offer relaxation that can enable patients to work in normal everyday lives. Because the medical profession raises its emphasis on cleaner, increasingly selective drug consumption and minimizing substance violence, healthcare workers actively evaluate all possible alternatives of the opioid to non-opioid opioids to mental therapy—by measuring possible potential advantages to everyone's dangers. If recent research and experiments of non-opioid analgesics remain ongoing, physicians may provide additional proof of potential successful application (Shah et al., 2015).

Chapter 11

Synthesized form of Conotoxin: Ziconotide

There are numerous sources with substantial elements around us, in the nature. The work of modern science is to take them to a certain stage where they can be used to make the necessary improvements in the various aspects. Medicines are one of the biggest concerns of scientists. Innovations have continued to take place through the years, with one thing in mind, "It has to be better." In recent years, so many experimental medicines have come out with the hope of delivering the best possible outcome. Clinical studies have been conducted for years to make the new drug more successful, followed by human trials. Researchers around the world have worked all day and night tirelessly to bring this progress forward. Nature has been the primary source for most medicines that have been synthesized or found. The available medicines have been extracted from it by scientists. Plants, soils, animals, and other living creatures have established this drug supply and have made scientists work on inventions. Sea is one of the major sources of medicine (McGivern, 2007).

A good number of drugs have been discovered which primarily originated from sea. These essential drugs are collected from different creatures living in the sea, which have revolutionized the modern paradigm of drug production. Cone snails are well-known marine gastropods that play the role of predators in the marine environment. There are more than 500 species of cone snails in the marine ecosystem, and they have been included as a single genus, cone, of the *Conidae* family. Cone snail has a venomous material within its shell that is used for hunting prey in the sea. There is a needle-like tooth in their body along with their venom gland used by snails to strike and hunt their prey. The venom produced by the cone snails is mainly peptide (Pope & Deer, 2013). There are several animals that are known as bioactive venoms. By encoding gene products, small long amino acids are often limited by disulfide

bonds. This encoding may result in an accelerated evaluation that acts as a strong cause of the differences in the distinctive characteristics of different snail venoms. As a result, different types of venoms target different parts of the marine species organs and display different mechanisms of action. These venoms have ligands working with ion channels, transporters, and receptors in the nervous system. Scientists have used this venom to prepare a drug that acts as a calcium channel blocker (Deer et al., 2019). It functions by being injected into the CSF (Cerebrospinal Fluid) and prevents the release of glutamate, which helps to alleviate pain. This extracted compound has been called Ziconotide, which is a non-opioid drug, making it an alternative option for opioid analgesics with several side-effects and adverse effects. With the recognition of FDA Ziconotide, it has now become one of the highest priority analgesic drugs under production in various research laboratories around the world (McGivern, 2007).

Many medicines are eligible for acute and recurrent illnesses. Traumatic pain, however recovery choices for severe pain the chronic pain is more minimal. Slightly to fairly acute pain will also be easily handled by OTC medicines such as acetaminophen, while extreme urgent acute medicines are pain needs powerful medications, including such opioid medications. It is the specific process for the operation of paracetamol is unclear, and even if That is a really healthy medication with minimal side effects, the latest findings show how serum concentration could be increased liver enzymes as given at large concentrations. Opioids are very efficient painkillers that conduct their anti-inflammatory activity by anguishing opioid receptors found in the spinal and supraspinal areas in the CNS (Barghi et al., 2015). Regrettably, antidepressants are guilty of generating severe side-effects, are vulnerable to relapse, and promote long-term or longer resistance to recurrent usage of this. Conotoxins, which poisons from ca represent possibly the best aid for the research of pain-free opioids, including analgesics. 800 types of aquatic snails including its *Conidae* family. Each animal has produced its very own special poison. Several animals have been defined mostly through genes coding their biologically

active toxin materials, and these genes are comparatively tiny proteins, the bulk of their architecturally limited by several disulfide bands (plenty of that 10-35 amino acids in size) (Fry et al., 2009). Most mono peptides are prone to more post-translation improvements. Cone snail toxin proteins are expressed in a superfamily of genomes, and a catalog of approximately 400 venom peptides has been identified in that species. Another notable characteristic of its genes that encode biologically active toxin constituents is its rapid evolution, perhaps amongst the most significant emerging gene factors identified to mono peptides (Li et al., 2017).

This outcome is that almost every cone type of snail seems to have its own recognizable toxin peptide supplement. That peptide of the particular venom possibly has a particular genetic goal in its biological relevance to the animal envenomated. Cone snail poisons have shown to be a valuable wellspring of very specific ligands throughout the nervous system through cell membranes, receptors as well as transporters. The general purpose of envenomation would be to change the biological nature of the intended species in order to favor the toxic attacker. However, most research on toxin description has studied specimens of the genus in the strict sense with a clear tendency against the creatures which target fish. There have been several analyses of small genera throughout the *Conidae* family. Cone snails aren't the first poisonous sea snails, and they contain just a handful of groups (Buczek et al., 2005).

A small part, including its range of poisonous snails. The Superfamily *Conoidea* is allocated to all taxa utilizing toxin like Conus. 2 major classes of poisonous conoides, namely augers (Terebridae family) as well as turrids, were conventionally named, in accordance to cone snails, quintessentially, *Turridae* family, that is obviously polyphenylene, and classified through at least six different other family groups. There are turrids, which comprise the largest range of venomous snails (Safavi-Hemami et al., 2019).

11.1 History of Ziconotide

The pharmacological actions of Ziconotide have been thoroughly studied in vivo also in vitro pre-clinical studies. Intrathecal Ziconotide throughout different animal studies of severe pain is indeed an effective antinociceptive therapeutic agent and has a totally new pathway for action involving a specific and effective blocker, including the presynaptic N-type calcium channels of its backbone (McDowell & Pope, 2016). This is actually just one N-type channel inhibitor officially licensed for medicinal usage. Research has proposed how Ziconotide provides some anti-compatible results by decreasing the activation throughout the spinal cord of pronociceptive neurons, which prevents the propagation of the pain signal. That therapeutic effectiveness of intrathecal Ziconotide seems compatible mostly with the theory that dorsal N forms of intracellular calcium being the main regulators of neuronal transmission in mammals, but its exact analgesic function in mammals also is not verified at just the moment. Quite a few recent articles are pertinent to the issues of this analysis and therefore are referenced, if necessary (Safavi-Hemami et al., 2019).

11.2 Sea Snail Venom as Analgesic

Conotoxins present within the venom of the cone-type snail, several of the scariest beings on the ocean, will constitute a new type of painkillers. Conotoxins are biologically active proteins present throughout the venom produced for prey and defense by aquatic cone snails. These have been used to research pain signaling as biochemical devices and then have the ability to be used in pain management. The advantage of conotoxins being they are far greater action than morphine and that, as compared to narcotics, they do not induce any signs of dependency (Sanford, 2013). Upwards of ten thousand sequences of conotoxin are already detected to date. University of Vienna's Chemistry Associate Professor Markus Muttenthaler along with his partners from the University of Queensland, Australia, were indeed the pioneers in venom

findings and already had a description of both the state, including its conotoxin science in chemical experiments (Pope & Deer, 2013).

In recent research, scientists also produced soluble conotoxin forms to image pain receptors in tissues. The aquatic predator cone snail is renowned for its successful poisoning technique that lets the comparatively sluggish species attract and protect its targets, such as fish or sea urchins. The cone snails paralyze and destroy their prey mostly with the aid of a quite specific and effective combination of venom peptides injection into its prey across a harpoon-like tool. “Cone snails might regulate their toxin distribution regardless of whether they are hunting or defending themselves," Muttenthaler stated. “The toxin of a protecting cone snail is of significant significance to pain studies because its formulation is intended to cause pain, and its constituents can also be utilized to analyze pathogenic processes," he added (McGivern, 2007).

11.3 Selected Route of Administration

The route of medication therapy is essentially the way medicine is used to detect, control, heal or handle multiple conditions and situations throughout the system. For a medication to achieve the intended beneficial activity, this should touch the membranes of the body and tissue cells in some form, and the medicine will be delivered appropriately. A substance's bioavailability specifically influences the route of administration, including its substance, which dictates the initiation as well as the extent of the pharmacological activity. The option of systemic delivery may be affected by several variables, including practice, clinical condition, the participation of the individual, that drug's existence as certain medications could only be successful on one path, for example, insulin the customer's age, the activity of gastrointestinal pH, stomach acid and digestion of the first passage, ETC.

Different administrative pathways are known as local pathways and systematic routes. The specific route describes the easiest way to administer a medication at the location where even the prescribed intervention is essential. If systemic drug absorption is wanted, drugs are typically delivered through 2 key pathways, and they are enteral route as well as the parenteral route. The interim pathway contains ingestion of the medication through the digestive tract, which requires delivery orally, sublingually, and rectally. Parenteral path, from the other side, applies to pathways of delivery without the intervention of medication ingestion through the intestinal system, namely injection pathways, for example, intravenous pathway, intra-muscular pathway, dermal pathway, etc., inhalation pathways as well as transdermal paths. Ziconotide is administered via an intrathecal route, which makes it different from the rest of the analgesics and painkillers.

11.3.1 Intrathecal Route of Administration –

Intrathecal as well as the epidural application of pharmaceutical drugs provide medication management intra-spinal pathways. Each pathway offers medicine to the brain fluid (CSF). The intrathecal distribution consists of the specific injection of the substance further into CSF and within the dorsal cord intrathecal area. However, in the subarachnoid space, the medicine administered needs to pass the dura layer to all the CSF (Boswell et al., 2007). Epidural delivered medicines will, therefore, enema. In enter routine distribution, although intrathecally distributed, narcotics are contained to the CSF throughout the spine and the neural ventricles. Intraspinal medication therapy was identified in the early 1980s after opioid receptors were detected in the spinal cord that since then have been used to relieve chronic distress in individuals that do not adapt to or suffer severe adverse reactions to certain analgesic medications. This intrathecal path enables the CSF to be delivered directly by circumventing the blood-brain barrier. Thus, it permits the distribution of lower prescription quantities and

decreases the appearance of adverse effects in contrast across drug absorption pathways (Chatelut et al., 1993).

The National Committee on Accreditation of Clinical Institutions developed rigorous pain control guidelines during 1999. The WHO developed a clear three-step "leader" strategy around 1986, starting for non-opioid medications, then leading to tougher narcotics, where possible (Staats et al., 2004). Adjunctive medicines such as anticonvulsants as well as antidepressants can also be utilized at either point as follows, non-opioid analgesics like anti-inflammatory nonsteroidal medicinal agents may be given in people that obtain no analgesics; in those situations where the pain is not rightly treated, it continues, or the dosage must escalate amid treatment using non-opioid medicinal products. Just several clinical directives also influenced treatment, such as a pain scale of the International Health Organization, so far of it is already formally included with some pain symptoms, like non-malignant persistent pain. Individuals require adjuvant care with oral or injectable narcotics in nearly 80 percent of patients who provide sufficient pain management. In Twenty percent of cases, although a type of complementary or intrusive treatment is expected to solve intransigent suffering, notwithstanding the WHO's vigorous dilutions of these therapies (Matsuki, 1983). For instance, negative digestive impacts, also including incontinence and vomiting, are approximated to become as high as 10 percent – 40 percent. During 1994, the WHO ladder was expanded as well as the mayo clinic pain relief conference held to incorporate intrusion pain medications such as spinal therapy. This paper reflects on these kinds of integrative therapies, including the administration of intrathecal medications. Sterilized isotonic medication products are intrathecal preparations. The intrathecal infusion amount is approximately 0.5 ml and 5 ml. The solubility of the drug may be a problem for lipid nanoparticles in a somewhat limited amount. Converting medications to liquid substances such as certain gentamicin sulfate or buffering will increase solubilization (Yaksh & Rudy, 1976).

CSF is a simple, pure aqueous solution lacking intestinal defense pathways, and its nutrient and carbohydrate presence will make it an optimal habitat for microbial growth. Aseptic methods can be used for injecting, preparing, and installation, and the medication mixture is processed using just a 0.2μm cap. Intrathecal formulas must therefore be clear of preservatives. Researches have demonstrated how arachnoid membranes (arachnoiditis), as well as nerve damage, maybe inflamed by additives, including preservatives and benzaldehyde. Neurotoxic effects are the major harmful consequence of the administration of intrathecal drugs through insufficient active ingredients, additives, viscosity improvers, and also the active agent itself. Intrathecal preparations must preferably include as few active ingredients as practicable, and their potential to induce neuroinflammation must be examined again for the active ingredient. Surgical intrathecal motors are ideal for the treatment of persistent intrathecal drugs (Goldstein et al., 1971). Pumps may be equipped through a percutaneous or completely inserted catheter externally, although devices can be completely installed. The Board Of health also released a study on intrathecal abuse control, recognizing its relevance and increasing understanding amongst the medical professionals and the Chief Operating Officer. An intrathecal drug delivery system is specialized expertise and should be conducted by properly qualified staff as per hospital guidelines, and protector Medication mistakes may be catastrophic and permanent. A detailed illustration of this is the intravenous infusion of alkaloid vinca medications (e.g., vincristine), which contributes to significant neuropsychiatric injury and mortality (Smith & Deer, 2009).

Chemotherapy intrathecal delivery is helpful in some cancer forms present in the CSF, for example, CNS leukemia including lymphoma, and in avoiding the atherosclerosis of cancer to just the CSF. Exponential chemotherapy contains constant concentrations of CSF cytotoxic medications. Due to the extremely limited half-life of cytotoxic drugs, the patient may have repeated intrathecal doses. Furthermore, medicines with a limited half-life do not accumulate

across the Plasma sufficient to allow a strong representation during the visual cortex and have an under the optimal clinical impact. The goal has been to decrease the extended process, promote wound healing, and eventually improve the treatment result by enhancing the delivery of medicines throughout the neuraxis. Injectable devices provide constant opioid delivery, but they may be uncomfortable and often threaten post-operative contamination since it requires surgery (Deer et al., 2019).

Intrathecally, antibiotic supply is suitable for CSF infections needing immediate and fast antibiotic care. In a micro-preemie sample with candidiasis pneumonia, the value of supplying antibiotics specifically to CSF by needle biopsy or intracerebral insertion has been emphasized. The research showed that the immediate distribution of antibiotics throughout the CSF of both the brain capillaries was necessary in extreme cases to increase life expectancy. Given the dangers of intrathecal treatment, the British Pain Society had reported that perhaps the provision in intrathecal medications is underutilized and that the care of persistent cancer pain and muscle spasms could become more readily accessible (Wallace et al., 2006).

Experiments suggesting increased standard of living and better survival of people with cancer obtaining intrathecal drug analgesia are backed by this argument, primarily because of a decline in postoperative complications (Chatelut et al., 1993). There is also a concern that the systemic administration of opium stimulates the immune response, thereby undermining longevity in people with cancer relative to intrathecally administered narcotics, which seems not to have a similar immune-suppressive impact. Many other substances as intrathecal analgesics have indeed been identified. Clonidine, an alpha-2 inhibitor, has also demonstrated to be successful in the treatment of neuropathy, complicated local pain as well as cancer distress, whether used alone but combined with an opioid analgesic. Gabapentin has a newly developed licensed for intrathecal analgesics in peripheral neuropathy pain control. Research from Buffalo University in the USA has demonstrated that the usage of a clinical intrathecal device for opiate

medication delivery gives successful analgesics to individuals who are not reacting to oral drugs with post-herpetic nerve pain. The research consisted of five patients aged 75. None of the participants had injuries, and both patients had enhanced pain management. Intrathecal analgesia can often utilize as an alternative to epidural analgesia to rapidly alleviate pain in the workplace. Intrathecal analgesia is beneficial since it may not delay labor development and increases the likelihood of vaginal not even of routine colonoscopy (Smith & Deer, 2009).

11.4 Intrathecal Administration of Ziconotide

Chronic pain is an intricate however multifaceted disease involving approximately a hundred million people and a global leader in impairment. Adjuvant persistent pain provides physicians with unique problems. In the form of specialized pain, tests described the pain as an adjuvant pain concept to quickly find system insertion appropriateness numerous scientific proof biomedical interventions did not meet the core objectives in an effective and reasonable manner (Wallace et al., 2006). Drug therapy Intrathecal (IT) has been developed as a critical persistent refractory pain therapy. Medical literature suggests the successful treatment of cancer type or non-cancer type etiology may be successfully managed by IT medication, namely neuropathic and nociceptive pain (Smith & Deer, 2009). The United States has licensed just two chemotherapeutic agents, morphine and ziconotide.

FDA is the only pain relief analgesic in individuals experiencing persistent adjuvant pain and authorized in IT medication with IT illnesses to date and ziconotide. In addition, ziconotide is licensed in individuals with assured IT medication as well as unaccepting to and therefore adjuvant to any procedure, for example, opioid analgesics, adjunctive medications, or IT morphine, for managing extreme severe conditions. Non-opioid IT analgesia would be specifically helpful to meet treatment concerns of individuals experiencing persistent refractory pain who might suffer detrimental consequences correlated with IT opioids, namely systemic

edema, hormone alteration, pulmonary disturbance, development of granulomas, drug resistance, even opioid-induced hyperalgesia. Ziconotide for the management of serious, persistent pain in patients who need IT analgesia is authorized throughout the European Union. In open statin trials, the effectiveness of IT ziconotide had also been identified in treating patients experiencing persistent refractory pain due to cancer and non-cancer linked pathophysiology. In a cumulative study of several trials, ziconotide found that a substantial pain reduction in comparison to placebo was given in a variety of etiologies, namely neuropathic, myelopathic, radiculopathy with cervical pain and unsuccessful back surgery syndrome. Based on such studies, in everything the therapeutic data regarding such product available, ziconotide is prescribed in the 2012 Polyanalgesic Consensus Conference (PACC) as first-line IT treatment respectively for neuropathic and nociceptive pain (McDowell & Pope, 2016).

The small therapeutic windows are generally defined as Ziconotide, and its tolerance pattern is similar to the level of medication rise that the successful amount applied. Careful ziconotide dosage control and titration with lower doses in relation to the rises with certain substances are also critical in ensuring sufficient effectiveness whereas mitigating harmful effects (Sanford, 2013). Consistency with ziconotide pharmacology after IT application is necessary to realize the effect of this drug on IT trials and long and persistent infusion. Cerebrospinal fluid flow mechanics in the dorsal cord is defined as heterogeneous due to a range of factors. Large quantities stream arising from the choroid plexus output for Cerebrospinal fluid and the emerging craniocaudal variation for a hydrostatic strain is historically known as major factors of CSF channel flow. However, analysis using new methods has shown that mass movement contributes to just 1% of CSF motion phenomena. Many powers, namely arterial pulse and pulmonary intracardiac friction being accepted as producing oscillatory, bidirectional as well

as craniocaudal motion pulsatile flux. Such a pulsatile-flow model indicates which oscillating motions spread drugs delivered intrathecally throughout the CSF (Hayek & Hanes, 2014).

In this sense, the intensity and amount of application and the bioactive compounds of the pharmaceutical substance further impact the delivery of an IT medicine. Drug delivery trends in the CSF, which are affected by such influences, can have therapeutic consequences for the effectiveness and protection of IT drugs. Ziconotide, in particular, is a moderately broad hydrophilic peptide that should consequently provide more analgesic and a greater half-life removal period than weaker lipid-soluble agents (Smith & Deer, 2009). Throughout preclinical and cell trials, the potential bioactivity of IT ziconotide is studied. A discrete IT injection bolus (10 mcg in 1 mL) or constant IT infusions is tracked utilizing the experimental prototype, including the beagle dogs (Staats et al., 2004).

The lateral CSF sample showed substantial peak intensity (3 minutes) and wakefulness clearance following the 10-mcg single dose of the bolus. Throughout persistent IT administration, lumbar CSF levels increased around 8 hours at the average values of 343 as well as 1380 ng/mL overall and stayed constant at a period between 343 and 1380 ng/mL only at the conclusion of medications. Overall, Ziconotide's cerebellar superconductivity is regular and compatible with standards of a broad water-soluble substance in this animal study. Moreover, clinical manifestations on agitation, muscle definition, and balance also weren't impaired after application of Bolus IT at the dosage stages, though they were impaired momentarily by continued IT induction (Vos et al., 2012). A research of 22 individual patients with established non-cancer-related pain 26 measured the CSF physicochemical properties of IT ziconotide and its association with ziconotide protection and effectiveness (Wallace et al., 2006). In many of these cases, an IT ziconotide at a dosage of 1, 5, 7,5, or 10 mcg was given at further than 1 hour per individual concentration of 200 mL bolus IT infusion. The estimated half-life of ziconotide in CSF was 4.5 hours for all level categories, and the dose relative and

longitudinal dosage pharmacokinetics in CSF were calculated throughout the dose range. Throughout this analysis, the accumulated sensitivity to ziconotide in CSF was a powerful predictor of pain reduction assessed as a CSF region underneath the concentration-time graph. The outcomes appeared compatible with both the pause between that ziconotide application and the full analgesic reaction. The obvious latency among both bolus IT ziconotide management and it pharm actional results, especially the occurrence and recovery of adverse behavioral reactions, seems to be the product of the lengthy infiltration into the central nervous parenchyma of this broad water-soluble compound. A main therapeutic consequence of the pharmacological effect of ziconotide would be that the preliminary IT ziconotide dose titration must take place at a rate that enables medication delivery inside the CSF and absorption into the location (Sanford, 2013).

This indicates that their titration for the original dosage can start with minimal dose changes that become no greater than once each 24 hours to maximize effectiveness and protection, to be addressed below 9. As preserving the occurrence of analgesic effectiveness may be reduced in patients with low dose ziconotide, physicians ought to regulate patient conditions by changing the rate of forwarding drug administration to analgesic benefit in response to a reasonable symptom severity of patients (Hayek & Hanes, 2014).

11.5 Indications of Ziconotide

Ziconotide is demonstrated in people with IT medication and also who unaccepting or refractory to all other medications like systemic analgesics, adjuvant medication, or IT narcotics in order to relieve serious, persistent pain. Ziconotide has been licensed as a monotherapy. Ziconotide is already being performed in systematic trials in conjunction with several other IT pump drugs (Prommer, 2005). It can be remembered that ziconotide also isn't contraindicated with the consequent usage of oral narcotic analgesics and alternative

treatments. 6 Many other non-IT drugs are provided in the 1.254 clinical trial participants, including 97% of patient populations staying on oral narcotics, 65% on anxiolytics, 50% on anticonvulsants, 46% on psychoactive treatment, and 33% on pain relief and control painkillers. Depressant drugs in individuals with different central nervous systems (CNSs) are at increased risk of agitation and lightheadedness or impaired awareness rate (Miljanich, 2004).

11.6 Stability and Storage Requirements of Ziconotide

Two specific and one secondary process can work in reducing the ziconotide content. Ziconotide within the pump deteriorates with time owing to human body temperature sensitivity at roughly 37° C. It seems to be often susceptible to shifts in pH, which needs a pH of approximately 5.0. Ziconotide is independent of additives but is prepared with abundant L-methionine that is needed to shield ziconotide from future oxidation deterioration (Stix, 2005). Oxygen dissolved in the IT storage vessel can be oxidated by ziconotide. As a peptide, its breakdown components being nontoxic and inert amino acids (Mathur, 2000). The intensity of ziconotide can often become volatile if diluted to both the operational pump levels. Which, for instance, dilutes the security offered by methionine from oxidation by a factor of 10 times whenever ziconotide gets diluted via 100 mcg/ml 1ml to 10 mcg/ml (Prommer, 2005). Usually, hardly any customized diluent is accessible at operating levels to dilute ziconotide, and diluting a 25mcg/ml vial isn't really less costly.

The ziconotide intensity may also exist at the original pump fill. Attention must also be given to the empty space or remaining volumes of Synchro Med EL as well as Synchro Med II pumps. The overall dead space capacity for Syncro Med-El being 2,4 ml and 1,4 ml also of 20- and 40-ml Synchro Med II pumps. One explanation that ziconotide rinse is advised then is dilution variable (Miljanich, 2004). Deposited in solubilized shape at -20°; once prepared, it shall have a shelf-life span of 39 months at such a temperature of 2-8°C. Infusion of ziconotide IT

demands cooling in transit and must be held at 2°C to 8°C temperatures. Ziconotide preparation really shouldn't be frozen, and extended light penetration ought to be avoided. Ziconotide should always be used 24 hours after the components of the container are withdrawn. This is focused on the US pharmacopeia guidelines for IT medicines in order to ensure product safety and impotence. Owing to its packaging insert, IT pumps historically subjected to undiluted (25 mcg/ml) ziconotide are steady for a minimum of 60 days while diluted ziconotide,100 mcg/ml diluted with conservatory-free saline to 25 mcg/ml, stay good in the pump for approximately 40 days. This was focused on a stability/time equation which is focused mostly on time taken in ziconotide (Shields et al., 2005). Within the scientific papers adopted by the Seventh Congress of the Global Conference on Neuromodulation in Rome, Italy, ziconotide (25 mcg/ml) seems relatively steady within realistic clinical conditions. 35 mg/ ml of hydromorphone maintains 88 percent of its original content for approximately 25 days without major improvements in hydromodification. It is less stable, however, with 35mg/mL of opioid and has a level of just 70% at 22 days.

Ziconotide (25mcg/ml) seems persistent at 2mg/ml of clonidine, and no agent exhibits deterioration at 28days.In combination with 25mcg/ml of ziconotide with 5mg/ml of bupiva, 90% of the original level stays stable for 22 days without any appreciation (Shields & Montenegro, 2007). Stability checks can be conducted at reduced clinically appropriate doses, as used in conjunction with both ziconotide and some other IT medicines. Structured trials supporting the safety of ziconotide were not reported if used in conjunction with either of the widely used IT drugs. Even so, for other IT medicines widely used during addition, there is a shortage of evidence. One in vitro analysis tests the safety of 50mg/ml morphine, 25mg/ml of bupivacaine, and 2 mg/ml of clonidine during controlled clinical settings at 37° Cover 90 days throughout the Synchro Med device.12 Whilst monotherapy is suggested, ziconotide usage in conjunction with some other IT care does not seem to have a protocol that is otherwise

implemented (Pope et al., 2016). With a time of Ziconotide knowledge, medical researchers were able to understand how the above prescription of the establishing 2.4 mcg/day dose is a reasonably high baseline. When an incompetent practitioner initiates ziconotide at a dosage of 2.4 mcg/day and raises them two or three days a week through 2.4 mcg/day, there is considerable danger of overweighting this medicine's small therapeutic window. The consequence is a large frequency of serious harmful incidents and a higher occurrence of ziconotide withdrawal attributable to intolerability. Ziconotide is correlated with harmful events such as nausea/obstruction, blurred vision, excessive gastritis, disturbing sight, or depression during the first few phases of treatment if the instruction on the implant kit begins at a rate of 2.4 mcg/day (Stix, 2005). Perceptual consequences, including memory failure, depression, and depression, appear to be further on at an average dosage of about 4.8 mcg/day for three weeks.

Consequently, it is prudent to titrate as much as weekly, to never override medicinal openings once a month. When toxic reactions arise, they typically improve after such a dosage decline. Initial adverse conditions typically cure within a few days, although late toxicities may take up to three more weeks. Inevitably, over-zealous titration may lead to the inability of such an important treatment to increase FDA consciousness of adverse drug events. Researchers recommend low beginning and gradual titration to reduce daily dosage harmful events, avoid unnecessary treatment, and generally offer better pain control and ziconotide performance (McGivern, 2006).

11.7 Safety Issues Regarding Intrathecal Administration

Ziconotide was extremely comprehensively tested as multiple controlled trials were performed. In a rather tough clinical community, sixteen percent of participants with ziconotide medication saw a drop of at least 30% in their pain levels . This is noteworthy and essential to bring into

perspective since most patients have a botched procedure, activation of the spinal cord, widespread narcotics, and insufficient intrathecal opioid treatment, estimated suffering a period of almost 15 years, and an estimated VASP (Vienna Ab initio Simulation Package) of 80 mm. Through clinical research procedures, an excess was reported leading to a 45x cumulative dosage accepted by the FDA in a clinical review (Shields & Montenegro, 2007). Hardly any cardiopulmonary impairment has arisen amid this unprecedented overdose, and no detox signs have been noted. There have been no recorded reports of ziconotide drug mortality in the research (Veizi et al., 2011).

This compares strongly with the overdose of opioids. Nausea, fatigue, urinary obstruction, ataxia, somnolence, sensory and sensory illusions, and voice issues occur through adverse effects. The levels of creatine kinase are being documented to be increased. The pharmaceutical medication package also includes a Black Box alert of the possible severe detrimental effects of individuals with a history of schizophrenia within the application, complications. Latest studies say that ziconotide side-effects are further ameliorated by reducing contaminating sensitivity to antidepressants or anticonvulsants (Classen et al., 2004).

11.8 Structural Aspects of Ziconotide

The ω-conotoxins, like, ω-GVIA (Omega conotoxin GVIA), ω-MVIIA (Omega conotoxin MVIIA), ω-MVIIC (Omega conotoxin MVIIC), reflect a conceptually linked community of polypeptide molecules contained primarily in the poison of some sea snail organisms (Mould et al., 2004). Tal-conotoxins usually associate with a strong affinity to voltage-driven calcium channels and powerfully obstruct calcium flow. Although structural preservation not only between the distinct Calcium Tests as well as among its functional groups onto voltage-activated calcium pathways, the basic characteristics of the multiple channels are essentially distinct from each other (Ellinor et al., 1994). ω-MVIIA comprises 25 amino acids; six of them

are cysteine variants, which are groups of three disulfide bond sequences is a hallmark attribute of the ÁNTI-conotoxins and guarantees that the protein is correctly folded and its shape stabilized into a small, well-identified natural state (Feng et al., 2003).

The instability of one of these disulfide bridges substantially weakens the stability of the MVIIA and allows the remainder more likely to be diminished. Amusingly, a native fragment of C-MVIIA, which is transcriptionally transformed into an amide group, is synthesized by Conus magus as a precursor peptide (Lin & Lin-Shiau, 1997). This glycine tends to improve the plyation capacity of the peptide in vivo through facilitating chemical associations that stabilize the indigenous configuration in comparison to other types of disulfide. Ziconotide seems to entangle with the α1B peptide (alpha-1B adrenergic receptor) porous region and therefore can intrude with calcium permeation through activating the platform. Researches have shown that the ziconotide prevents N-type calcium magnetic fields in both indigenous cells and heterologous mechanisms (Smith et al., 2002). The majority of indigenous molecules have a wide range of calcium channels, which results in ziconotide hardly least partly limits strong voltage-activated calcium magnetic fields in the distinguishable IMR32 cells, rat preferable ganglion cervical neurons as well as rat hippocampal brain regions. Calcium currents again from the interpretation of the α1B site in HEK (human embryonic kidney) molecules also decrease in ziconotide. TSA–201 neurons as well as Xenopus laevis oocytes (Luchian, 2001). Experimentally, ziconotide shows no or very little utilization heavy reliance in their protective action, likely reflecting the same binding energy for site rest, accessible and inactivated states. Of benefit is that the inactivation of ziconotide in α1B-mediated calcium current flow might well differ in function over whether or not auxiliary subunits α2d and β are expressed as well (Feng et al., 2003). The strategies throughout the chimeric-calcium medium α1 subunit and the studies in amino acid substitution had already shared light that the large α1B

peptide areas can identify the signaling pathway and assess block attributes by ziconotide (Staats et al., 2004).

The linking point for ziconotide tends to coincide with either the ω GVIA situated near the P-clock of DIII. The α1B peptide includes, in particular, an EF-like motif situated along the DIII P-loop. This EF-like handheld pattern will attach calcium, which promotes its penetration through the stream pores. In addition, this intent may very well influence the adhesion of a tetra conotoxin (Newcomb et al., 1995). Recent studies have already shown that glycine-1326, as well as glutamate-1332 genetic changes, impact not only the permeability of calcium, as well as the preventing qualities of canal osteoarthritis. Glycine-1326 looks specific to constrain direct toxin exposure to its active site while also reducing block start rates and augmenting block reproducibility (Sanford, 2013). Amusingly enough, the amino acid genetic variations downwind, including its EF hand-like pattern, are distinct to ziconotide as well as ω GVIA, which embrace the theory that one ‘s corresponding side chains are intertwining, but really not similar (Sanger et al., 2000). Because N-type calcium sites are so powerfully blocked, ziconotide has been demonstrated to be an appropriate blocker of neurotransmission in numerous nervous system synapses. In reality, ziconotide is also used as a method for defining the contribution of N-type calcium channels in the synapse formation of central and peripheral synapses because of its subgroup precision. Ziconotide, therefore, blocks the norepinephrine release of hippocampal neurons in the periphery (Wen et al., 2005). Compatible mostly with co-location of that same N-type calcium channels as well as P substances in principal afferent neuron central nervous ports, ziconotide powerfully prevents the depolarized launch of P from spiny cord slices. It involves N-type calcium channels throughout the central processing of pain receptors and indicates that it could add value to the ziconotide's antinociceptive effectiveness. Because of the prominent position of calcium type P sites in triggering the quality of

neurotransmitters at the neuromuscular junction, much more sphincter jerking movements are unavoidable (Fox, 1995).

11.9 In Vivo Studies of Ziconotide

Ziconotide is already identified through intrathecal therapy as just an effective and lengthy antinociceptive compound (Mould et al., 2004). Analytical results mostly on antinociceptive activities of ziconotide have been collected throughout the early 1990s; however, detailed experiments have indeed been carried out to describe their effects in various pain experiments for animals for information on effectiveness and dosage (Dickenson & Sullivan, 1987). These findings have shown that ziconotide is more active than morphine and is especially successful in recurrent (minute-to-hour) and chronic pain systems. In contrast, pain management assessments appear to become less successful. Ziconotide may also be successful in multiple intrathecal medication regimes, such as a single intravenous infusion and acute or chronic continuous infusion.

Given its good potency, the dorsal ziconotide therapeutic index continues also to be limited, and its antinociceptive results in animals are frequently correlated with a maximum dosage of mechanical defects. While ziconotide in healthy mice does not pass the blood-brain barrier easily, this could contribute to hypotension unless it reaches the systemic circulation. These changes in blood pressure seem at least partly also to be induced by an impairment for sympathetic neurotransmission, possibly as either a consequence of N-type calcium channel blocking in sensitive nerve endings. Potential ziconotide anti-nociceptive symptoms having been reported together under a number of medicating protocols involving acute and chronic treatment in different animal pain experiments (Haley et al., 1990). The proof of ziconotide's clear anti-skeletal potency during prolonged administration demonstrates convincingly that apart from opioids, the medication is not related to the production of resistance. This finding

has substantial consequences for the long-term care of ziconotide in individuals. The observational data also indicates that N-type calcium canals, which are articulated at several locations, mostly along pain pathways, are fundamentally essential for the propagation of pain signals (Malmberg & Yaksh, 1994). These areas might include the residual site of nerve trauma, whereby calcium N-type pathways tend to be included in the production of chronic recurrent neuronal operation during nerve injury scenarios. Moreover, calcium-type N channels are of great importance for transmitting arriving nociceptive stimuli through secondary sensory neurons in the dorsal cord, and those in the ventromedial medulla, including its rostral medulla, can trigger downward pain facilitating systems, which have been shown to help sustain neuropathic pain conditions (Wang & Gao, et al., 2000).

Table 2- In vivo studies of ziconotide

Inflammatory pain studies Kaolin (3%) and carrageenan (3%) injected into the knee-joint	**Continuous infusion** 1 h infusion pre-induction: 100 μM at 5 μL/min. prevented the development of secondary heat hyperalgesia. Continuous infusion beginning 4 h post-induction: 100 μM at 5 μL/min.reversed established secondary heat hyperalgesia within 1 h.
Complete Freund's adjuvant (CFA)injected into the paw	**Bolus injection** -5 days post-CFA injection: ID50 16 per mol

Neuropathic Pain Studies Chronic constriction injury (sciatic) Partial nerve injury (sciatic)	**Continuous infusion-** Mechanical allodynia: ID50 10 ng/h following 3-day infusion **Bolus injection-** Heat hyperalgesia: 100 pmol reversed heat hyperalgesia Heat hyperalgesia: no significant effect on heat hyperalgesia at 100 pmol

11.10 Clinical Studies of Ziconotide

Three major randomized, two-blind, placebo-controlled Phase 3 clinical trials were developed to ensure the protection and analgesic effectiveness of intrathecal ziconotide in more than 550 individuals. Both participants in such trials had extreme persistent pain with cancerous and/or non-malignant causes even though it was important that their pain was insufficiently regulated by other medications, namely opioids, to be included in the studies (Wallace et al., 2006). The analgesic effectiveness of ziconotide within chronic dose concepts is tested by such clinical studies in order to assess the propensity for sensitivity to this medication. A smaller, placebo-controlling clinical trial found that ziconotide can be successful in the treatment of neuropathy and perhaps even the analgesic potency of ziconotide in a post-liturgical environment. Quite a few recently reported articles addressing medical interactions with ziconotide are eligible (Rauck et al., 2006). The very first ziconotide crucial study concerned people with persistent cancer or AIDS. Throughout this study, 68 people obtained ziconotide both for preliminary 5-6-day duration by persistent intrathecal infusion accompanied by stabilization of participants who reacted to therapy. The beginning dosage for ziconotide was low, but it could regularly be

raised (at periods of 12 to 24 hours) until adequate pain relief, the maximal level of 2.4 μg/h or leading to better is achieved (Atanassoff, 2000).

Reasonable to full pain relief was obtained for many other patients throughout the initial stage with an expected reduction of 53 percent in pain thresholds, as measured on a perceived stress pain severity scale (VASPI). Particularly within maintenance activities, there was no lack of analgesic potency, showing that humans do not grow ziconotide sensitivity (Safavi-Hemami et al., 2019). More commonly than those in the placebo population, harmful reactions were reported, and their frequency was usually minimized by beginning a medication injection at smaller concentrations or by utilizing small or less regular dosage intervals (Kristipati et al., 1994). The second seminal analysis tested the protection and effectiveness of ziconotide in patients with established, mainly neuropathic non-malignant pain. Throughout this analysis, 169 participant patients obtained ziconotide at a smaller dosage (always 0,1 or 0,4 μg/h) with a 24-h doubling level before the pain reduction is adequate, a maximal level (2,4 or 7,0 μg/h, dependent on the initial dose) or negative impacts were accomplished. Because in the first study, individuals obtaining ziconotide had mild to maximum pain relief, however in this second trial, the overall VASPI decrease was smaller. Over the recovery phase at which the potency of ziconotide was preserved, respondents kept obtaining the prescription (Gohil et al., 1994). Even more, by lowering the dosage or level of titration or discontinuing the medicine, the side effects may be addressed. The third cornerstone analysis examined the efficacy and usefulness of ziconotide in 220 people, most neuropathic with unsolvable extreme persistent pain (Kristipati et al., 1994).

The study was carried out in reaction to regulatory questions regarding the high frequency and seriousness of adverse effects and the higher incidence of patient slacker over the first two studies. The nature of this final experiment, therefore, varied from that of the previous trials on a variety of important points like these were based on a gradual titration cycle (increases

not more often than every 24 hours, it provided for the smaller daily dose (0.9 μg/h). It was broader than every 24 hours (Yaksh et al., 2012). Important pain reduction was obtained in most ziconotide-treated clients, and an overall VASPI increase was reported at 15 percent. The size of the drop was less than in the experiments conducted, and this appears to be associated mostly with smaller concentrations used. In the ziconotide, treatment participants have ingested 24% fewer opioids than the control group. Adverse effects were identified in this study at low therapeutic doses of ziconotide, but many of these were classified mild or moderate and progressed progressively after medicine infusion had begun (Staats et al., 2004). In general, intrathecal ziconotide is a new, useful and reliable analgesic drug that may be utilized to alleviate extreme persistent cancerous or non-malignant pain symptomatically. It is indeed successful in preventing pain triggered by surgery. Because as ziconotide is intrathecally delivered to individuals, it is possible to assume that its clinical mode of operation entails, in the spinal cord, another pre-synaptic N-type calcium pathway which decreases the activation by afferents neuromuscular junctions and reduces the synaptic excitement throughout the brain areas of second sensory nerve transmissions (Brose et al., 1997).

Essentially, ziconotide is not detrimental and does not tend to cause sensitivity growth. It is also an analgesic treatment appropriate for lengthy use though the patient has managed to take the medication for yet more than seven years in at least one situation. Given someone using an infusion device to transmit medication to something like the intrathecal area, the intensity of ziconotide that accesses the N-type calcium channels throughout the central ends of the main sensory neurons throughout the dorsal horn is quite hard to predict or monitor. Furthermore, the optimum dosage of the medication must be empirically established. Nonetheless, the ziconotide clinical benefit appears to be limited and harmful reactions (mainly psychological and neurological) are possible, specifically if the dosage is quickly administered, a large dose

is provided, or indeed the dose rises too much. The positive news is, though, that if harmful effects arise, they typically overcome by lowering the dosage or lowering the level of drug treatment (Wang & Gao, et al., 2000).

Chapter 12

Schematical Representation of Project Methodology



Figure 3- Schematical Representation of the Project Methodology

Chapter 13

Discussion

Numerous medicines are used for the treatment of acute and chronic inflammatory pain, although treatments for the treatment of persistent neuropathic pain are much more restricted. Mild to serious pain may also be successfully controlled through over-the-counter medicines also including acetaminophen; however, extreme acute pain needs more analgesics such as opioid narcotics. The precise mode of action of acetaminophen remains unclear, and while it is a relatively healthy medication with few side effects, the latest analysis indicates that it could raise serum levels of liver enzymes while administered at large doses (Pope & Deer, 2013).

Opioid medications are very powerful pain relievers which demonstrate their analgesia through excruciating opioid receptors situated at just the dorsal as well as supraspinal locations of the central nervous system. Worse still, narcotics may trigger severe side-effects, being vulnerable to abuse, and encourage sensitivity with extended or regular usage. Medications further included relieving inflammatory pain contain non-steroidal anti-inflammatory drugs (NSAIDs), including ibuprofen and naproxen. Such medicines being non-selective antagonists, including their two main cyclo-oxygenase (COX) isoforms. COX inhibitors function by reducing the development of prostaglandins, endogenous substances believed to sensitize residual and core sensory neurons. After all, such non-selective medications are linked with both the production of gastric ulcers, possibly owing to repression of COX-1. On another side, specific COX-2 blockers have caused fewer gastrointestinal complications and have been commonly prescribed for many years. However, after controversial disclosures concerning possible cardiovascular complications, certain COX-2 inhibitors have been pulled from the field, and others are still alert involving significant hazards. Medications licensed again for management of neuropathic pain are carbamazepine, gabapentin, pregabalin as well as

duloxetine. In additament, some tricyclic antidepressants, antiepileptic medications, and antiarrhythmic medicines are widely administered off for relieving the pain of neuropathy (Barnett, 2001). Most of these medications tend to work by preventing the operation of the sodium and calcium neural voltage-gated channels in such a non-selective fashion. Even so, such medications typically need large doses, have a high rate of non-responsive drugs and offer sub-optimal effectiveness. As a consequence, there are substantial prospects for the research and production of new medications for the treatment of serious and persistent pain, but it should be noted that regulatory authorities will insist that drugs be very effective until they are accepted on the marketplace (McGivern, 2007).

Ziconotide has also been identified as a powerful and long-lasting antinociceptive medication when administrated mostly on the intrathecal path. Exploratory proof of the antinociceptive activity of ziconotide was first obtained in the 90s, and ever since then, detailed experiments are being performed to describe its impact in several animal models of pain. These tests have shown that ziconotide is much more powerful than morphine and is especially useful in cases of acute pain and chronic pain. In contrast, it appears to be less successful in severe pain studies. It is also necessary to remember that ziconotide may be effective in a number of intrathecal dosing, namely single bolus injection and acute or chronic continuous infusion. Given its potent potency, the therapeutic index of spinal ziconotide continues to be poor, and relatively high motor deficits frequently follow its antinociceptive results in animals. While the blood-brain barrier in ordinary organisms does not readily cross ziconotide, it can induce hypotension if it reaches the bloodstream (Miljanich, 2004).

This effect on blood pressures tends to be caused at least partly by suppressing supportive neurotransmission, possibly as a consequence of N-type calcium channel obstruction in sympathetic nerve terminals. That anti-nociceptive effectiveness of ziconotide in animal models of distress is clearly complicated. However, the findings mentioned are indeed

especially inspiring with regard to both the mode of action of ziconotide and the function of N-type calcium channels in the regulation of distress signal transmission (Shields et al., 2007). The relative usefulness of ziconotide in acute against chronic pain experiments can indicate improvements in the transcription levels of calcium channel subunits during circumstances of neuronal hyperexcitability. Consequently, N-type calcium channels can be more fundamentally significant in oversensitive situations, and their involvement in the transmitting of pain may be more substantial during chronic pain conditions instead of under acute pain circumstances.

Conversely, it is understood that the pharmacokinetics of the N-type calcium channel may differ based on its subunit structure, at least in heterologous expression models. If this process were to be repeated in N-neuronal calcium canals, tissue infection nerve injury-induced changes in the subunit structure of the canals might contribute to enhanced susceptibility to ziconotide restricting behavior (Sanford, 2013). Intrathecal ziconotide is indeed a new, effective, and long-lasting analgesic treatment that can be used for symptomatic relief of extreme persistent cancerous as well as non-malignant pain. It is, therefore, successful in preventing surgical-induced pain (Wang, Pettus, et al., 2000).

Because ziconotide is delivered intrathecally to individuals, it is encouraging to believe that its clinical mode of action entails mainly the blockade of presynaptic N-type calcium channels throughout the spinal cord, contributing to a decrease throughout the production of pronociceptive neurotransmitters of primary afferent neuromuscular junctions and decreased synaptic activation of secondary sensory neurons throughout the dorsal cord (Rauck et al., 2006). Crucially, ziconotide also seems to be non-addictive and does not seem to affect the production of resistance. It is also an analgesic treatment that is appropriate for long-term use and, in at least 1 situation, the patient has managed to take the medication for more than 7 years. Given the usage of an infusion pump to distribute the medication directly to the intrathecal space, it is very hard to predict or monitor the local concentration of ziconotide that can reach

the N-type calcium channels situated at the central terminals of the primary sensory neurons in the dorsal horn.(Newcomb et al., 2000) Thus, the optimum dosage of the drug continues to be calculated empirically. However, the therapeutic index of ziconotide appears to be poor and negative reactions, mainly psychological and neurological, may occur, specifically when the medication is absorbed fast, when the dosage is heavy or when the dose is increased too often. Nevertheless, the positive sign is that unless harmful effects arise, they typically overcome whenever the dosage is decreased, or the risk of disease progression is minimized (P. Staats & Yaksh, 2006).

Ziconotide is a big accomplishment in modern pain management, but considering its potent analgesic potency, there is a substantial potential for progress. The possibility emerges largely from the peptide existence of the medication and its need for intrathecal administration to achieve analgesic potency with a decreased risk for side-effects in the systemic and central nervous system (McDowell & Pope, 2016). As a consequence, drug development experts are contemplating different methods to find and produce new, internally active, N-type calcium channel-specific inhibitors that could be preferable to ziconotide. High analgesic potency and increased protection and tolerability, compared to both ziconotide and opioid, is a crucial aspect of the next generation N-type calcium channel disrupting medication (Wallace et al., 2006). This aim may be accomplished by investigating strategies to classify substances that show greater selectivity for sensory neuron-specific forms of the N-type calcium channel and exhibit a use-dependent calcium channel obstruction function.

As far as the suggested technique is concerned, there are reported to exist several kinetically discrete versions of the calcium channel 5-0071B subunit, several of which tend to be unique to peripheral neurons. In fact, a dorsal horn ganglion-specific version has lately been described in rats, and this finding indicates that individual N-type calcium channels can also display sensory neuron-specific splice variants which could be selectively tailored for better and more

efficient pain therapy. Calcium-dependent application of N-type channel inhibitors, one suggestion is to classify substances that ideally attach to open and/or inactivated channel states (Mould et al., 2004). If efficient, this strategy is anticipated to contribute to the discovery of substances that can suppress calcium inflow more successfully throughout high-frequency neuronal firing, what happens in hypersensitive pain conditions, and far less successfully during low-frequency neuronal firing. It is anticipated that new molecules with an application mode of action would give either a strong analgesic potency or an increased therapeutic index compared to ziconotide (Staats et al., 2004).

Neuromed Pharmaceuticals is indeed a leader in this area and has successfully collaborated alongside Merck & Co. to develop NMED-160 (N-type calcium channel blocker), the oral-available, use-dependent N-type calcium channel blocker in Phase ii studies for a range of pain disorders. During preclinical research, this compound showed a wide efficiency potential in animal studies of neuropathic as well as inflammatory pain but also had a reasonable protection record (Wang, Gao, et al., 2000). Nevertheless, it needs to be seen why this medication is analgesic in those with extreme chronic pain. Strengthened simplicity of implementation is also a beneficial aspect of a new medication that could negate the need for intrathecal treatment, which presently hampers extensive research and usage of ziconotide. Admittedly, if a new N-type calcium channel blocker could be administered systemically, this might not just improve transmission to current patients, but may also expand the size of the patient pool that is supposed to gain from analgesia through this process.

The added advantage of systemic delivery will be to decrease the possibility of contamination involved with a surgically inserted medication delivery unit (McGivern, 2007). While it is potentially feasible to recognize peptide substances that can pass the blood-brain barrier, – for example, the analog ziconotide SNX-194 the developmental obstacles will be challenging to solve owing to the sensitivity of such substances to N-type calcium channels across the entire

nervous system, including the sympathetic neurons involved in the regulation of blood pressure. In particular, owing to its extensive distribution throughout the endocrine system, it should be remembered that medications attacking N-type calcium channels can have many consequences on various organs that depend on such channels to fulfill their usual biological mechanisms. Therefore, centered on existing information, a structurally novel, orally active small molecule with a use-dependent mode of operation is believed to become the best suitable candidate model for new generation N-type calcium channel blocking drugs for application in the management of extreme pain (McGivern, 2007).

Chapter 14

Conclusion

Ziconotide is a significant discovery in modern pain management. Since it has potent analgesic activity, therefore there is a substantial potential for further development. The possibility emerges mainly from the peptide's existence in the drug and it is needed for intrathecal administration to achieve analgesic potency with a decreased risk for side effects in the body. Scientists are working regularly to discover new drugs with better efficacy and fewer side effects and ADRs (Adverse drug reaction). Ziconotide is considered as one of the gifts from nature in sea snail venom, which has given excellent results in medicines associated with painkilling in acute and chronic pain generated from cancer and different surgeries.

Chapter 15

Future Work

Ziconotide is a significant achievement in contemporary pain management, but with its immense analgesic efficacy, there is still a lot of room for improvement. The probability stems primarily from the peptide present in the drug and the need for intrathecal administration to maintain analgesic efficacy with a lower chance of cardiovascular and central nervous system adverse effects. As a result, drug developers are considering a variety of approaches for discovering and manufacturing novel, biologically activated, N-type calcium channel-specific inhibitors that may be a better alternative to ziconotide. A key feature of the next generation N-type calcium channel blocking drug is its strong analgesic efficacy and improved safety and tolerability as opposed to both ziconotide and opioid. This goal could be achieved by looking at techniques for classifying compounds that have a higher selectivity for sensory neuron-specific variants of the N-type calcium channel and have a calcium channel disruption mechanism that is use-dependent. This approach is expected to aid in the development of drugs that can effectively inhibit calcium inflow during the high-frequency neuronal fire, which occurs in overly sensitive pain situations, but not during low-frequency neuronal firing. In comparison to ziconotide, new molecules are expected to have either a good analgesic efficacy or a higher therapeutic index.

References

Alkhoury, F., Burnweit, C., Malvezzi, L., Knight, C., Diana, J., Pasaron, R., Mora, J., Nazarey, P., Aserlind, A., & Stylianos, S. (2012). A prospective study of safety and satisfaction with same-day discharge after laparoscopic appendectomy for acute appendicitis. *Journal of Pediatric Surgery*, *47*(2), 313–316. https://doi.org/10.1016/j.jpedsurg.2011.11.024

Alvarez, V., Arttamangkul, S., & Williams, J. T. (2001). A RAVE about opioid withdrawal. In *Neuron* (Vol. 32, Issue 5, pp. 761–763). Cell Press. https://doi.org/10.1016/S0896-6273(01)00530-X

Atanassoff, P. (2000). Ziconotide, a new n-type calcium channel blocker, administered intrathecally for acute postoperative pain*1, *2. *Regional Anesthesia and Pain Medicine*, *25*(3), 274–278. https://doi.org/10.1016/s1098-7339(00)90010-5

Babb, M., Koren, G., & Einarson, A. (2010). Treating pain during pregnancy. In *Canadian Family Physician* (Vol. 56, Issue 1, pp. 25–27). College of Family Physicians of Canada. www.motherisk.org

Ballantyne, J. C., & Mao, J. (2003). Opioid Therapy for Chronic Pain. *New England Journal of Medicine*, *349*(20), 1943–1953. https://doi.org/10.1056/nejmra025411

Barghi, N., Concepcion, G. P., Olivera, B. M., & Lluisma, A. O. (2015). Comparison of the venom peptides and their expression in closely related conus species: Insights into adaptive post-speciation evolution of conus exogenomes. *Genome Biology and Evolution*, *7*(6), 1797–1814. https://doi.org/10.1093/gbe/evv109

Barnett, M. (2001). Alternative opioids to morphine in palliative care: A review of current practice and evidence. In *Postgraduate Medical Journal* (Vol. 77, Issue 908, pp. 371–378). The Fellowship of Postgraduate Medicine. https://doi.org/10.1136/pmj.77.908.371

Berde, C. B., & Sethna, N. F. (2002). Analgesics for the Treatment of Pain in Children. *New England Journal of Medicine*, *347*(14), 1094–1103. https://doi.org/10.1056/nejmra012626

Bolay, H., & Moskowitz, M. A. (2002). Mechanisms of pain modulation in chronic syndromes. In *Neurology* (Vol. 59, Issue 5 SUPPL. 2). Lippincott Williams and Wilkins. https://doi.org/10.1212/wnl.59.5_suppl_2.s2

Boswell, M. V., Trescot, A. M., Datta, S., Schultz, D. M., Hansen, H. C., Abdi, S., Sehgal, N., Shah, R. V., Singh, V., Benyamin, R. M., Patel, V. B., Buenaventura, R. M., Colson, J. D., Cordner, H. J., Epter, R. S., Jasper, J. F., Dunbar, E. E., Atluri, S. L., Bowman, R. C., … Manchikanti, L. (2007). Interventional techniques: Evidence-based practice guidelines in the management of chronic spinal pain. In *Pain Physician* (Vol. 10, Issue 1, pp. 7–111). Association of Pain Management Anesthesiologists. https://jhu.pure.elsevier.com/en/publications/interventional-techniques-evidence-based-practice-guidelines-in-t-3

Bovill, J. G. (1997). Mechanisms of actions of opioids and non-steroidal anti-inflammatory drugs. *European Journal of Anaesthesiology, Supplement*, *128*(5), 9–15. https://doi.org/10.1097/00003643-199705001-00003

Brose, W. G., Gutlove, D. P., Luther, R. R., Bowersox, S. S., & McGuire, D. (1997). Use of intrathecal SNX-111, a novel, N-type, voltage-sensitive, calcium channel blocker, in the management of intractable brachial plexus avulsion pain. *Clinical Journal of Pain*, *13*(3), 256–259. https://doi.org/10.1097/00002508-199709000-00012

Buczek, O., Bulaj, G., & Olivera, B. M. (2005). Conotoxins and the posttranslational modification of secreted gene products. In *Cellular and Molecular Life Sciences* (Vol. 62, Issue 24, pp. 3067–3079). Springer. https://doi.org/10.1007/s00018-005-5283-0

Campbell, J. N., & Meyer, R. A. (2006). Mechanisms of Neuropathic Pain. In *Neuron* (Vol. 52, Issue 1, pp. 77–92). Neuron. https://doi.org/10.1016/j.neuron.2006.09.021

Chang, G., Chen, L., & Mao, J. (2007). Opioid Tolerance and Hyperalgesia. *Med Clin N Am*, *91*, 199–211. https://doi.org/10.1016/j.mcna.2006.10.003

Chatelut, E., Kim, T., & Kim, S. (1993). A slow-release methotrexate formulation for intrathecal chemotherapy. *Cancer Chemotherapy and Pharmacology*, *32*(3), 179–182. https://doi.org/10.1007/BF00685832

Chen, J. (Steven), & Sehdev, J. S. (2019). Physiology, Pain. In *StatPearls*. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/pubmed/30969611

Christie, M. J. (1991). Mechanisms of opioid actions on neurons of the locus coeruleus. In *Progress in Brain Research* (Vol. 88, Issue C, pp. 197–205). https://doi.org/10.1016/S0079-6123(08)63809-1

Christie, MacDonald J., Connor, M., Vaughan, C. W., Ingram, S. L., & Bagley, E. E. (2000). Cellular actions of opioids and other analgesics: Implications for synergism in pain relief. *Clinical and Experimental Pharmacology and Physiology*, *27*(7), 520–523. https://doi.org/10.1046/j.1440-1681.2000.03291.x

Chwistek, M. (2017). Recent advances in understanding and managing cancer pain. In *F1000Research* (Vol. 6). Faculty of 1000 Ltd. https://doi.org/10.12688/f1000research.10817.1

Classen, A. M., Wimbish, G. H., & Kupiec, T. C. (2004). Stability of admixture containing morphine sulfate, bupivacaine hydrochloride, and clonidine hydrochloride in an implantable infusion system. *Journal of Pain and Symptom Management*, *28*(6), 603–611. https://doi.org/10.1016/j.jpainsymman.2004.04.011

Davis, M. P., & Mehta, Z. (2016). Opioids and Chronic Pain: Where Is the Balance? In *Current Oncology Reports* (Vol. 18, Issue 12). Current Medicine Group LLC 1. https://doi.org/10.1007/s11912-016-0558-1

De Nadal, M., Munar, F., Poca, A., Sahuquillo, J., Garnacho, A., & Rosselló, J. (2000). Cerebral hemodynamic effects of morphine and fentanyl in patients with severe head injury: Absence of correlation to cerebral autoregulation. *Anesthesiology*, *92*(1), 11–19. https://doi.org/10.1097/00000542-200001000-00008

Deer, T. R., Pope, J. E., Hanes, M. C., & McDowell, G. C. (2019). Intrathecal therapy for chronic pain: A review of morphine and ziconotide as firstline options. *Pain Medicine (United States)*, *20*(4), 784–798. https://doi.org/10.1093/pm/pny132

Deer, T. R., Prager, J., Levy, R., Burton, A., Buchser, E., Caraway, D., Cousins, M., De Andrés, J., Diwan, S., Erdek, M., Grigsby, E., Huntoon, M., Jacobs, M., Kim, P., Kumar, K., Leong, M., Liem, L., McDowell, G., Panchal, S. J., … Mekhail, N. (2012). Polyanalgesic Consensus Conference-2012: Recommendations on Trialing for Intrathecal (Intraspinal) Drug Delivery: Report of an Interdisciplinary Expert Panel. *Neuromodulation: Technology at the Neural Interface*, *15*(5), 420–435. https://doi.org/10.1111/j.1525-1403.2012.00450.x

Dews, T. E., & Mekhail, N. (2004). Safe use of opioids in chronic noncancer pain. In *Cleveland Clinic Journal of Medicine* (Vol. 71, Issue 11, pp. 897–904). Cleveland Clinic Educational Foundation. https://doi.org/10.3949/ccjm.71.11.897

Dickenson, A. H., & Sullivan, A. F. (1987). Peripheral origins and central modulation of subcutaneous formalin-induced activity of rat dorsal horn neurones. *Neuroscience Letters*, *83*(1–2), 207–211. https://doi.org/10.1016/0304-3940(87)90242-4

Dinakar, P., & Stillman, A. M. (2016). Pathogenesis of Pain. *Seminars in Pediatric Neurology*,

23(3), 201–208. https://doi.org/10.1016/j.spen.2016.10.003

Dreifuss, J. A., Griffin, M. L., Frost, K., Fitzmaurice, G. M., Potter, J. S., Fiellin, D. A., Selzer, J., Hatch-Maillette, M., Sonne, S. C., & Weiss, R. D. (2013). Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study. *Drug and Alcohol Dependence*, *131*(1–3), 112–118. https://doi.org/10.1016/j.drugalcdep.2012.12.010

Eitan, S., Emery, M. A., Bates, M. L. S., & Horrax, C. (2017). Opioid addiction: Who are your real friends? In *Neuroscience and Biobehavioral Reviews* (Vol. 83, pp. 697–712). Elsevier Ltd. https://doi.org/10.1016/j.neubiorev.2017.05.017

Ellinor, P. T., Zhang, J. F., Horne, W. A., & Tsien, R. W. (1994). Structural determinants of the blockade of N-type calcium channels by a peptide neurotoxin. *Nature*, *372*(6503), 272–275. https://doi.org/10.1038/372272a0

Feng, Z. P., Doering, C. J., Winkfein, R. J., Beedle, A. M., Spafford, J. D., & Zamponi, G. W. (2003). Determinants of inhibition of transiently expressed voltage-gated calcium channels by ω-conotoxins GVIA and MVIIA. *Journal of Biological Chemistry*, *278*(22), 20171–20178. https://doi.org/10.1074/jbc.M300581200

Finch, P. M., Roberts, L. J., Price, L., Hadlow, N. C., & Pullan, P. T. (2000). Hypogonadism in patients treated with intrathecal morphine. *Clinical Journal of Pain*, *16*(3), 251–254. https://doi.org/10.1097/00002508-200009000-00011

Finnerup, N. B. (2019). Nonnarcotic Methods of Pain Management. *New England Journal of Medicine*, *380*(25), 2440–2448. https://doi.org/10.1056/nejmra1807061

Fishbain, D. A., Rosomoff, H. L., & Rosomoff, R. S. (1992). Drug abuse, dependence, and addiction in chronic pain patients. In *Clinical Journal of Pain* (Vol. 8, Issue 2, pp. 77–85).

Clin J Pain. https://doi.org/10.1097/00002508-199206000-00003

Foreman, R. D., Garrett, K. M., & Blair, R. W. (2015). Mechanisms of cardiac pain. *Comprehensive Physiology*, *5*(2), 929–960. https://doi.org/10.1002/cphy.c140032

Fornasari, D. (2012). Pain mechanisms in patients with chronic pain. In *Clinical Drug Investigation* (Vol. 32, Issue SUPPL. 1, pp. 45–52). https://doi.org/10.2165/11630070-000000000-00000

Fox, J. A. (1995). Irreversible and reversible blockade of IMR32 calcium channel currents by synthetic MVIIA and iodinated MVIIC ω-conopeptides. *Pflügers Archiv European Journal of Physiology*, *429*(6), 873–875. https://doi.org/10.1007/BF00374813

Freye, E., Levy, J. V., Freye, E., & Levy, J. V. (2008). Mechanism of Action of Opioids and Clinical Effects. In *Opioids in Medicine* (pp. 85–187). Springer Netherlands. https://doi.org/10.1007/978-1-4020-5947-6_2

Fry, B. G., Roelants, K., Champagne, D. E., Scheib, H., Tyndall, J. D. A., King, G. F., Nevalainen, T. J., Norman, J. A., Lewis, R. J., Norton, R. S., Renjifo, C., & Rodríguez De La Vega, R. C. (2009). The toxicogenomic multiverse: Convergent recruitment of proteins into animal venoms. In *Annual Review of Genomics and Human Genetics* (Vol. 10, pp. 483–511). https://doi.org/10.1146/annurev.genom.9.081307.164356

Gohil, K., Bell, J. R., Ramachandran, J., & Miljanich, G. P. (1994). Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium-channel antagonist, SNX-230 (ω-conopeptide MVIIC). *Brain Research*, *653*(1–2), 258–266. https://doi.org/10.1016/0006-8993(94)90398-0

Goldstein, A., Lowney, L. I., & Pal, B. K. (1971). *Stereospecific and Nonspecific Interactions of the Morphine Congener Levorphanol in Subcellular Fractions of Mouse Brain* (Vol.

68, Issue 8).

Gross, J. L., Perate, A. R., & Elkassabany, N. M. (2019). Pain Management in Trauma in the Age of the Opioid Crisis. In *Anesthesiology Clinics* (Vol. 37, Issue 1, pp. 79–91). W.B. Saunders. https://doi.org/10.1016/j.anclin.2018.09.010

Gupta, A., & Bah, M. (2016). NSAIDs in the Treatment of Postoperative Pain. In *Current Pain and Headache Reports* (Vol. 20, Issue 11). Current Medicine Group LLC 1. https://doi.org/10.1007/s11916-016-0591-7

Halawi, R., Saad Aldin, E., Baydoun, A., Dbouk, H., Nahleh, Z., Nasser, Z., & Tfayli, A. (2012). Physical symptom profile for adult cancer inpatients at a Lebanese cancer unit. *European Journal of Internal Medicine*, *23*(8). https://doi.org/10.1016/j.ejim.2012.08.018

Haley, J. E., Sullivan, A. F., & Dickenson, A. H. (1990). Evidence for spinal N-methyl-d-aspartate receptor involvement in prolonged chemical nociception in the rat. *Brain Research*, *518*(1–2), 218–226. https://doi.org/10.1016/0006-8993(90)90975-H

Harhra, N. A., & Basaleem, H. O. (2012). Trends of breast cancer and its management in the last twenty years in Aden and adjacent governorates, Yemen. *Asian Pacific Journal of Cancer Prevention : APJCP*, *13*(9), 4347–4351. https://doi.org/10.7314/apjcp.2012.13.8.4247

Hayek, S. M., & Hanes, M. C. (2014). Intrathecal therapy for chronic pain: Current trends and future needs. In *Current Pain and Headache Reports* (Vol. 18, Issue 1). Current Science Inc. https://doi.org/10.1007/s11916-013-0388-x

Hoffmann, N. G., Olofsson, O., Salen, B., & Wickstrom, L. (1995). Prevalence of abuse and dependency in chronic pain patients. *Substance Use and Misuse*, *30*(8), 919–927. https://doi.org/10.3109/10826089509055820

Hsu, J. R., Mir, H., Wally, M. K., & Seymour, R. B. (2019). Clinical Practice Guidelines for Pain Management in Acute Musculoskeletal Injury. In *Journal of orthopaedic trauma* (Vol. 33, Issue 5, pp. e158–e182). NLM (Medline). https://doi.org/10.1097/BOT.0000000000001430

Hussain, S. A. (2013). Comprehensive update on cancer scenario of Bangladesh. *South Asian Journal of Cancer*, *2*(4), 279. https://doi.org/10.4103/2278-330x.119901

Jimenez Andrade, J. M., & Mantyh, P. (2010). Cancer Pain: From the Development of Mouse Models to Human Clinical Trials. In *Translational Pain Research: From Mouse to Man*. CRC Press/Taylor & Francis. http://www.ncbi.nlm.nih.gov/pubmed/21882467

Jones, C. M., Campopiano, M., Baldwin, G., & McCance-Katz, E. (2015). National and state treatment need and capacity for opioid agonist medication-assisted treatment. *American Journal of Public Health*, *105*(8), e55–e63. https://doi.org/10.2105/AJPH.2015.302664

Kieffer, B. L., & Evans, C. J. (2002). Opioid tolerance-in search of the holy grail. In *Cell* (Vol. 108, Issue 5, pp. 587–590). Cell Press. https://doi.org/10.1016/S0092-8674(02)00666-9

Kim, Y.-D. (2019). Opioid: toward an effective strategy for better use. *The Korean Journal of Pain*, *32*(2), 67–68. https://doi.org/10.3344/kjp.2019.32.2.67

Kiyatkin, E. A. (2019). Respiratory depression and brain hypoxia induced by opioid drugs: Morphine, oxycodone, heroin, and fentanyl. In *Neuropharmacology* (Vol. 151, pp. 219–226). Elsevier Ltd. https://doi.org/10.1016/j.neuropharm.2019.02.008

Klein, M., Krarup, P. M., Kongsbak, M. B., Ågren, M. S., Ggenur, I., Jorgensen, L. N., & Rosenberg, J. (2012). Effect of postoperative diclofenac on anastomotic healing, skin wounds and subcutaneous collagen accumulation: A randomized, blinded, placebo-controlled, experimental study. *European Surgical Research*, *48*(2), 73–78.

https://doi.org/10.1159/000336208

Klein, Mads, Gögenur, I., & Rosenberg, J. (2012). Postoperative use of non-steroidal anti-inflammatory drugs in patients with anastomotic leakage requiring reoperation after colorectal resection: Cohort study based on prospective data. *BMJ (Online)*, *345*(7879). https://doi.org/10.1136/bmj.e6166

Kremer, M., Salvat, E., Muller, A., Yalcin, I., & Barrot, M. (2016). Antidepressants and gabapentinoids in neuropathic pain: Mechanistic insights. In *Neuroscience* (Vol. 338, pp. 183–206). Elsevier Ltd. https://doi.org/10.1016/j.neuroscience.2016.06.057

Kremer, M., Yalcin, I., Goumon, Y., Wurtz, X., Nexon, L., Daniel, D., Megat, S., Ceredig, R. A., Ernst, C., Turecki, G., Chavant, V., Théroux, J. F., Lacaud, A., Joganah, L. E., Lelievre, V., Massotte, D., Lutz, P. E., Gilsbach, R., Salvat, E., & Barrot, M. (2018). A dual noradrenergic mechanism for the relief of neuropathic allodynia by the antidepressant drugs duloxetine and amitriptyline. *Journal of Neuroscience*, *38*(46), 9934–9954. https://doi.org/10.1523/JNEUROSCI.1004-18.2018

Kristipati, R., Nádasdi, L., Tarczy-Hornoch, K., Lau, K., Miljanich, G. P., Ramachandran, J., & Bell, J. R. (1994). Characterization of the binding of omega-conopeptides to different classes of non-L-type neuronal calcium channels. *Molecular and Cellular Neurosciences*, *5*(3), 219–228. https://doi.org/10.1006/mcne.1994.1026

Kynast, K. L., Russe, O. Q., Geisslinger, G., & Niederberger, E. (2013). Novel findings in pain processing pathways: Implications for miRNAs as future therapeutic targets. In *Expert Review of Neurotherapeutics* (Vol. 13, Issue 5, pp. 515–525). https://doi.org/10.1586/ern.13.34

Lee, J. D., Friedmann, P. D., Kinlock, T. W., Nunes, E. V., Boney, T. Y., Hoskinson, R. A., Wilson, D., McDonald, R., Rotrosen, J., Gourevitch, M. N., Gordon, M., Fishman, M.,

Chen, D. T., Bonnie, R. J., Cornish, J. W., Murphy, S. M., & O'Brien, C. P. (2016). Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders. *New England Journal of Medicine*, *374*(13), 1232–1242. https://doi.org/10.1056/nejmoa1505409

Li, Q., Barghi, N., Lu, A., Fedosov, A. E., Bandyopadhyay, P. K., Lluisma, A. O., Concepcion, G. P., Yandell, M., Olivera, B. M., & Safavi-Hemami, H. (2017). Divergence of the venom exogene repertoire in two sister species of Turriconus. *Genome Biology and Evolution*, *9*(9), 2211–2225. https://doi.org/10.1093/gbe/evx157

Li, Z., Aninditha, T., Griene, B., Francis, J., Renato, P., Serrie, A., Umareddy, I., Boisseau, S., & Hadjiat, Y. (2018). Burden of cancer pain in developing countries: A narrative literature review. In *ClinicoEconomics and Outcomes Research* (Vol. 10, pp. 675–691). Dove Medical Press Ltd. https://doi.org/10.2147/CEOR.S181192

Lin, M. J., & Lin-Shiau, S. Y. (1997). Multiple types of Ca2+ channels in mouse motor nerve terminals. *European Journal of Neuroscience*, *9*(4), 817–823. https://doi.org/10.1111/j.1460-9568.1997.tb01431.x

Ling, W., Mooney, L., & Hillhouse, M. (2011). Prescription opioid abuse, pain and addiction: Clinical issues and implications. *Drug and Alcohol Review*, *30*(3), 300–305. https://doi.org/10.1111/j.1465-3362.2010.00271.x

Luchian, T. (2001). The influence exerted by the β3 subunit on MVIIA ω-conotoxin binding to neuronal N-type calcium channels. *Biochimica et Biophysica Acta - Biomembranes*, *1512*(2), 329–334. https://doi.org/10.1016/S0005-2736(01)00336-4

Lynch, S. S., Cheng, C. M., & Yee, J. L. (2006). Intrathecal ziconotide for refractory chronic pain. In *Annals of Pharmacotherapy* (Vol. 40, Issues 7–8, pp. 1293–1300). https://doi.org/10.1345/aph.1G584

Malmberg, A. B., & Yaksh, T. L. (1994). Voltage-sensitive calcium channels in spinal nociceptive processing: Blockade of N- and P-type channels inhibits formalin-induced nociception. *Journal of Neuroscience*, *14*(8), 4882–4890. https://doi.org/10.1523/jneurosci.14-08-04882.1994

Mathur, V. S. (2000). Ziconotide: A new pharmacological class of drug for the management of pain. *Seminars in Anesthesia*, *19*(2), 67–75. https://doi.org/10.1053/sa.2000.6787

Matsuki, A. (1983). Nothing new under the sun - A Japanese pioneer in the clinical use of intrathecal morphine. In *Anesthesiology* (Vol. 58, Issue 3, pp. 289–290). American Society of Anesthesiologists. https://doi.org/10.1097/00000542-198303000-00023

McCormack, K. (1994). The Spinal Actions of Nonsteroidal Anti-Inflammatory Drugs and the Dissociation between their Anti-Inflammatory and Analgesic Effects. *Drugs*, *47*(5), 28–45. https://doi.org/10.2165/00003495-199400475-00006

McDowell, G. C., & Pope, J. E. (2016). Intrathecal Ziconotide: Dosing and Administration Strategies in Patients With Refractory Chronic Pain. *Neuromodulation*, *19*(5), 522–532. https://doi.org/10.1111/ner.12392

McGivern, J. G. (2006). Targeting N-type and T-type calcium channels for the treatment of pain. In *Drug Discovery Today* (Vol. 11, Issues 5–6, pp. 245–253). Drug Discov Today. https://doi.org/10.1016/S1359-6446(05)03662-7

McGivern, J. G. (2007). Ziconotide: A review of its pharmacology and use in the treatment of pain. *Neuropsychiatric Disease and Treatment*, *3*(1), 69–85. https://doi.org/10.2147/nedt.2007.3.1.69

Miljanich, G. (2004). Ziconotide: Neuronal Calcium Channel Blocker for Treating Severe Chronic Pain. *Current Medicinal Chemistry*, *11*(23), 3029–3040.

https://doi.org/10.2174/0929867043363884

Morgan, M. M., & Christie, M. J. (2011). Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human. In *British Journal of Pharmacology* (Vol. 164, Issue 4, pp. 1322–1334). Wiley-Blackwell. https://doi.org/10.1111/j.1476-5381.2011.01335.x

Morrison, L. J., & Morrison, R. S. (2006). Palliative Care and Pain Management. In *Medical Clinics of North America* (Vol. 90, Issue 5, pp. 983–1004). Med Clin North Am. https://doi.org/10.1016/j.mcna.2006.05.016

Mould, J., Yasuda, T., Schroeder, C. I., Beedle, A. M., Doering, C. J., Zamponi, G. W., Adams, D. J., & Lewis, R. J. (2004). The α 2δ auxiliary subunit reduces affinity of ω-conotoxins for recombinant N-type (Ca v2.2) calcium channels. *Journal of Biological Chemistry*, *279*(33), 34705–34714. https://doi.org/10.1074/jbc.M310848200

Nauta, M., Landsmeer, M. L. A., & Koren, G. (2009). Codeine-acetaminophen versus nonsteroidal anti-inflammatory drugs in the treatment of post-abdominal surgery pain: a systematic review of randomized trials. In *American Journal of Surgery* (Vol. 198, Issue 2, pp. 256–261). Elsevier. https://doi.org/10.1016/j.amjsurg.2008.11.044

Nersesyan, H., & Slavin, K. V. (2007). Current aproach to cancer pain management: Availability and implications of different treatment options. In *Therapeutics and Clinical Risk Management* (Vol. 3, Issue 3, pp. 381–400). Dove Press. /pmc/articles/PMC2386360/?report=abstract

Nestler, E. J. (1996). Under siege: The brain on opiates. In *Neuron* (Vol. 16, Issue 5, pp. 897–900). Cell Press. https://doi.org/10.1016/S0896-6273(00)80110-5

Newcomb, R., Abbruscato, T. J., Singh, T., Nadasdi, L., Davis, T. P., & Miljanich, G. (2000).

Bioavailability of Ziconotide in brain: Influx from blood, stability, and diffusion. *Peptides*, *21*(4), 491–501. https://doi.org/10.1016/S0196-9781(00)00175-3

Newcomb, R., Palma, A., Fox, J., Gaur, S., Lau, K., Chung, D., Cong, R., Bell, J. R., Home, B., Nadasdi, L., & Ramachandran, J. (1995). SNX-325, A Novel Calcium Antagonist from the Spider Segestria florentina. *Biochemistry*, *34*(26), 8341–8347. https://doi.org/10.1021/bi00026a015

Perekopskiy, D., Afzal, A., Jackson, S. N., Muller, L., Woods, A. S., & Kiyatkin, E. A. (2020). The Role of Peripheral Opioid Receptors in Triggering Heroin-induced Brain Hypoxia. *Scientific Reports*, *10*(1), 1–13. https://doi.org/10.1038/s41598-020-57768-3

Plummer, M., de Martel, C., Vignat, J., Ferlay, J., Bray, F., & Franceschi, S. (2016). Global burden of cancers attributable to infections in 2012: a synthetic analysis. *The Lancet Global Health*, *4*(9), e609–e616. https://doi.org/10.1016/S2214-109X(16)30143-7

Pope, J. E., & Deer, T. R. (2013). Ziconotide: A clinical update and pharmacologic review. *Expert Opinion on Pharmacotherapy*, *14*(7), 957–966. https://doi.org/10.1517/14656566.2013.784269

Pope, J. E., Deer, T. R., Bruel, B. M., & Falowski, S. (2016). Clinical Uses of Intrathecal Therapy and Its Placement in the Pain Care Algorithm. *Pain Practice*, *16*(8), 1092–1106. https://doi.org/10.1111/papr.12438

Prommer, E. E. (2005). Ziconotide: Can we use it in palliative care? In *American Journal of Hospice and Palliative Medicine* (Vol. 22, Issue 5, pp. 369–374). Weston Medical Publishing. https://doi.org/10.1177/104990910502200510

Raffaeli, W., & Arnaudo, E. (2017). Pain as a disease: An overview. *Journal of Pain Research*, *10*, 2003–2008. https://doi.org/10.2147/JPR.S138864

Rau, K. M., Chen, J. S., Wu, H. B., Lin, S. F., Lai, M. K., Chow, J. M., Huang, M. L., Wang, C. J., Tai, C. J., Hwang, W. L., Lu, Y. C., Chan, C. H., & Hsieh, R. K. (2015). The impact of pain control on physical and psychiatric functions of cancer patients: A nation-wide survey in Taiwan. *Japanese Journal of Clinical Oncology*, *45*(11), 1042–1049. https://doi.org/10.1093/jjco/hyv124

Rauck, R. L., Wallace, M. S., Leong, M. S., MineHart, M., Webster, L. R., Charapata, S. G., Abraham, J. E., Buffington, D. E., Ellis, D., & Kartzinel, R. (2006). A Randomized, Double-Blind, Placebo-Controlled Study of Intrathecal Ziconotide in Adults with Severe Chronic Pain. *Journal of Pain and Symptom Management*, *31*(5), 393–406. https://doi.org/10.1016/j.jpainsymman.2005.10.003

Reed, M. D. (2013). The Balance Between Effective Opioid-Based Pain Management and Patient Safety: Can It Be Achieved? *The Journal of Pediatric Pharmacology and Therapeutics*, *18*(4), 264–268. https://doi.org/10.5863/1551-6776-18.4.264

Safavi-Hemami, H., Brogan, S. E., & Olivera, B. M. (2019). Pain therapeutics from cone snail venoms: From Ziconotide to novel non-opioid pathways. In *Journal of Proteomics* (Vol. 190, Issue 2017). Elsevier B.V. https://doi.org/10.1016/j.jprot.2018.05.009

Sanford, M. (2013). Intrathecal ziconotide: A review of its use in patients with chronic pain refractory to other systemic or intrathecal analgesics. In *CNS Drugs* (Vol. 27, Issue 11, pp. 989–1002). https://doi.org/10.1007/s40263-013-0107-5

Sanger, G. J., Ellis, E. S., Harries, M. H., Tilford, N. S., Wardle, K. A., & Benham, C. D. (2000). Rank-order inhibition by ω-conotoxins in human and animal autonomic nerve preparations. *European Journal of Pharmacology*, *388*(1), 89–95. https://doi.org/10.1016/S0014-2999(99)00830-4

Schug, S. A., Daly, H. C. S., & Stannard, K. J. D. (2011). Pathophysiology of Pain. In

Mechanisms of Vascular Disease: A Reference Book for Vascular Specialists. University of Adelaide Press. http://www.ncbi.nlm.nih.gov/pubmed/30485023

Shah, S., Banh, E. T., Koury, K., Bhatia, G., Nandi, R., & Gulur, P. (2015). Pain Management in Pregnancy: Multimodal Approaches. In *Pain Research and Treatment* (Vol. 2015). Hindawi Publishing Corporation. https://doi.org/10.1155/2015/987483

Shields, D., & Montenegro, R. (2007). Chemical stability of ziconotide-clonidine hydrochloride admixtures with and without morphine sulfate during simulated intrathecal administration. *Neuromodulation*, *10*(SUPPL. 1), 6–11. https://doi.org/10.1111/j.1525-1403.2007.00130.x

Shields, D., Montenegro, R., & Aclan, J. (2007). Chemical stability of admixtures combining ziconotide with baclofen during simulated intrathecal administration. *Neuromodulation*, *10*(SUPPL. 1), 12–17. https://doi.org/10.1111/j.1525-1403.2007.00132.x

Shields, D., Montenegro, R., & Ragusa, M. (2005). Chemical stability of admixtures combining ziconotide with morphine or hydromorphone during simulated intrathecal administration. *Neuromodulation*, *8*(4), 257–263. https://doi.org/10.1111/j.1525-1403.2005.00034.x

Siegel, S. (1976). Morphine analgesic tolerance: Its situation specificity supports a Pavlovian conditioning model. *Science*, *193*(4250), 323–325. https://doi.org/10.1126/science.935870

Smith, H. S., & Deer, T. R. (2009). Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain. In *Therapeutics and Clinical Risk Management* (Vol. 5, Issue 1, pp. 521–534). Ther Clin Risk Manag. https://doi.org/10.2147/tcrm.s4438

Smith, M. T., Cabot, P. J., Ross, F. B., Robertson, A. D., & Lewis, R. J. (2002). The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinociception

after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices. *Pain*, *96*(1–2), 119–127. https://doi.org/10.1016/S0304-3959(01)00436-5

Staats, P. S., Yearwood, T., Charapata, S. G., Presley, R. W., Wallace, M. S., Byas-Smith, M., Fisher, R., Bryce, D. A., Mangieri, E. A., Luther, R. R., Mayo, M., McGuire, D., & Ellis, D. (2004). Intrathecal Ziconotide in the Treatment of Refractory Pain in Patients with Cancer or AIDS: A Randomized Controlled Trial. *Journal of the American Medical Association*, *291*(1), 63–70. https://doi.org/10.1001/jama.291.1.63

Staats, P., & Yaksh, T. L. (2006). Ziconotide: Profile report. In *Drugs and Therapy Perspectives* (Vol. 22, Issue 8, pp. 7–9). Springer. https://doi.org/10.2165/00042310-200622080-00002

Stein, C., & Lang, L. J. (2009). Peripheral mechanisms of opioid analgesia. In *Current Opinion in Pharmacology* (Vol. 9, Issue 1, pp. 3–8). Elsevier. https://doi.org/10.1016/j.coph.2008.12.009

Stix, G. (2005). A toxin against pain. *Scientific American*, *292*(4), 70–75. https://doi.org/10.1038/scientificamerican0405-88

Trescot, A. M., Helm, S., Hansen, H., Benyamin, R., Glaser, S. E., Adlaka, R., Patel, S., Manchikanti, L., Datta, S., Sehgal, N., Colson, J., Jordan, A., & Lee, M. (2008). Opioids in the management of chronic non-cancer pain: An update of American Society of the Interventional Pain Physicians' (ASIPP) guidelines. In *Pain Physician* (Vol. 11, Issue SPEC. ISS. 2).

Urquhart, E. (1993). Central analgesic activity of nonsteroidal antiinflammatory drugs in animal and human pain models. *Seminars in Arthritis and Rheumatism*, *23*(3), 198–205. https://doi.org/10.1016/S0049-0172(05)80041-1

Veizi, I. E., Hayek, S. M., Narouze, S., Pope, J. E., & Mekhail, N. (2011). Combination of Intrathecal Opioids with Bupivacaine Attenuates Opioid Dose Escalation in Chronic Noncancer Pain Patients. *Pain Medicine*, *12*(10), 1481–1489. https://doi.org/10.1111/j.1526-4637.2011.01232.x

Vieira, C., Brás, M., & Fragoso, M. (2019). Opioids for cancer pain and its use under particular conditions: A narrative review. In *Acta Medica Portuguesa* (Vol. 32, Issue 5, pp. 388–399). CELOM. https://doi.org/10.20344/amp.10500

Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., Abraham, J., Ackerman, I., Aggarwal, R., Ahn, S. Y., Ali, M. K., Almazroa, M. A., Alvarado, M., Anderson, H. R., Anderson, L. M., … Murray, C. J. L. (2012). Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. *The Lancet*, *380*(9859), 2163–2196. https://doi.org/10.1016/S0140-6736(12)61729-2

Walco, G. A., Cassidy, R. C., & Schechter, N. L. (1994). Pain, Hurt, and Harm -- The Ethics of Pain Control in Infants and Children. *New England Journal of Medicine*, *331*(8), 541–544. https://doi.org/10.1056/nejm199408253310812

Wallace, M. S., Charapata, S. G., Fisher, R., Byas-Smith, M., Staats, P. S., Mayo, M., McGuire, D., & Ellis, D. (2006). Intrathecal ziconotide in the treatment of chronic nonmalignant pain: A randomized, double-blind, placebo-controlled clinical trial. *Neuromodulation*, *9*(2), 75–86. https://doi.org/10.1111/j.1525-1403.2006.00055.x

Wang, S. (2019). Historical Review: Opiate Addiction and Opioid Receptors. In *Cell Transplantation* (Vol. 28, Issue 3, pp. 233–238). SAGE Publications Ltd. https://doi.org/10.1177/0963689718811060

Wang, Y. X., Gao, D., Pettus, M., Phillips, C., & Bowersox, S. S. (2000). Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats. *Pain*, *84*(2–3), 271–281. https://doi.org/10.1016/S0304-3959(99)00214-6

Wen, L., Yang, S., Qiao, H., Liu, Z., Zhou, W., Zhang, Y., & Huang, P. (2005). SO-3, a new O-superfamily conopeptide derived from Conus striatus, selectively inhibits N-type calcium currents in cultured hippocampal neurons. *British Journal of Pharmacology*, *145*(6), 728–739. https://doi.org/10.1038/sj.bjp.0706223

Whistler, J. L., Chuang, H. H., Chu, P., Jan, L. Y., & Von Zastrow, M. (1999). Functional dissociation of μ opioid receptor signaling and endocytosis: Implications for the biology of opiate tolerance and addiction. *Neuron*, *23*(4), 737–746. https://doi.org/10.1016/S0896-6273(01)80032-5

Wiffen, P. J., Wee, B., Derry, S., Bell, R. F., & Moore, R. A. (2017). Opioids for cancer pain - an overview of Cochrane reviews. In *Cochrane Database of Systematic Reviews* (Vol. 2017, Issue 7). John Wiley and Sons Ltd. https://doi.org/10.1002/14651858.CD012592.pub2

Williams, J. T., Christie, M. J., & Manzoni, O. (2001). Cellular and synaptic adaptations mediating opioid dependence. In *Physiological Reviews* (Vol. 81, Issue 1, pp. 299–343). American Physiological Society. https://doi.org/10.1152/physrev.2001.81.1.299

Woolf, C. J. (1995). Somatic pain: Pathogenesis and prevention. *British Journal of Anaesthesia*, *75*(2), 169–176. https://doi.org/10.1093/bja/75.2.169

Yaksh, T., Fisher, C., Hockman, T., & Wiese, A. (2016). Current and Future Issues in the development of spinal agents for the management of pain. *Current Neuropharmacology*, *14*(999), 1–1. https://doi.org/10.2174/1570159x14666160210142547

Yaksh, T. L., De Kater, A., Dean, R., Best, B. M., & Miljanich, G. P. (2012). Pharmacokinetic analysis of ziconotide (SNX-111), an intrathecal N-type calcium channel blocking analgesic, delivered by bolus and infusion in the dog. *Neuromodulation*, *15*(6), 508–519. https://doi.org/10.1111/j.1525-1403.2012.00479.x

Yaksh, T. L., & Rudy, T. A. (1976). Analgesia mediated by a direct spinal action of narcotics. *Science*, *192*(4246), 1357–1358. https://doi.org/10.1126/science.1273597

Yamanaka, T., & Sadikot, R. T. (2013). Opioid effect on lungs. *Respirology*, *18*(2), 255–262. https://doi.org/10.1111/j.1440-1843.2012.02307.x